

REMARKS

Claims 28-30 and 52-69 are presently pending. Claims 28-30 have been amended. No new matter is entered upon entry of these amendments. Claims 1-27 and 31-33 were previously canceled. Claims 34-51 were previously canceled and reinstated as claims 52-69.

I. Rejections Under 35 U.S.C. § 112, First Paragraph

Claims 28-30 and 52-69 continue to stand rejected under 35 U.S.C. §112, first paragraph, for alleged lack of enablement. Applicant continues to traverse this rejection for all of the reasons of record, and respectfully requests reconsideration in view of the following additional remarks.

**Applicant's *In Vivo* Claims in the Issued Parent Application
are Presumed to be Valid and Thus Enabled under 35 U.S.C.
282**

The examiner's rejection of the claims under the enablement requirement of 35 U.S.C. § 112, first paragraph, focuses on the purported lack of *in vivo* efficacy of antisense. Office Action, pages 2-3. Applicant notes that his parent application¹, is also directed to antisense oligonucleotide inhibition using compounds comprising a plurality of covalently-bound 2'-modified nucleosides. Issued claim 8 of the parent application reads as follows:

8. A method of inhibiting the production or activity of a protein in an organism, comprising contacting said organism with a compound of claim 1.

The compounds of claim 1 are directed to a plurality of covalently-bound 2'-modified nucleosides. Since the parent application is a United States patent, claim 8 is presumed to be valid and thus enabled. 35 U.S.C. § 282. Similarly, claims 16 and 27 of the parent patent to methods of inhibiting the production or activity of a protein in an organism, comprising contacting the organism with compounds comprising a plurality of covalently-bound 2'-modified nucleosides of claims 9 and 17, respectively, are also presumed valid and thus enabled.

In making the instant enablement rejection, the examiner relies upon the Opalinska and Gewirtz reference (Nature Reviews, 2002, 1:503-514) as evidence of the unpredictability

¹ Serial No. 09/349,007, filed July 7, 1999, now U.S. Pat. No. 6,326,358 (the "parent patent", attached as Exhibit A).

in the antisense art. However, the examiner's analysis of the issue is incomplete as it does not appear to take into account applicant's parent case or the fact that there has been some success with antisense oligonucleotides as therapeutic agents. See, *e.g.*, specification, page 2, lines 14-22:

"One method for inhibiting specific gene expression is with the use of oligonucleotides, especially oligonucleotides which are complementary to a specific target messenger RNA (mRNA) sequence. Several oligonucleotides are currently undergoing clinical trials for such use. Phosphorothioate oligonucleotides are presently being used as therapeutic agents in human clinical trials against various disease states, including use as antiviral agents."

Moreover, Applicant is providing herewith a copy of a decision received from the Board of Patent Appeals and Interferences in Appeal No. 2004-1394, Application No. 09/348,106 (Exhibit B). Following similar reasoning, the Board vacated the examiner's enablement rejection of claims directed to methods of inhibiting expression of a gene in cells or tissues², or treating a disease or condition, associated with the expression of a gene in an animal³, by the administration of certain oligonucleotides. Accordingly, the instant rejection under 35 U.S.C. § 112, first paragraph, is improper and should be withdrawn.

II. Rejections Under 35 U.S.C. § 112, Second Paragraph

Claims 28-30 and 52-69 stand rejected under 35 U.S.C. § 112, second paragraph, for allegedly failing to comply with the written description requirement. The Office Action states that the claim language of the term "contacting" is considered "to be extremely broad, encompassing any method of inhibition *in vivo* and further, to treatments of any disease." (Office Action, page 6, second paragraph, first sentence) Although Applicant does not necessarily agree, Applicant has amended claims 28-30 to indicate that the contacting method reduces the undesired production of a protein in an organism. Support for these amendments is provided, for example, in the claims and throughout the specification as originally filed.

² "9. A method of inhibiting expression of a gene comprising administering to cells or tissues the oligonucleotides of claim 1, said oligonucleotides having a sequence complementary to a portion of said gene."

³ "10. A method of treating a disease or condition, associated with the expression of a gene, in an animal, comprising administering to said animal the oligonucleotide of claim 1, said oligonucleotide having a sequence complementary to said gene, immune stimulation in said animal being reduced thereby."

DOCKET NO.: ISIS-4847
Application No.: 09/965,551
Office Action Dated: July 28, 2004

PATENT

Accordingly, Applicant respectfully requests that these rejections under 35 U.S.C. § 112, second paragraph, be withdrawn.

Conclusions:

Applicant requests the Examiner to:

- (1) enter the amendments to claims 28-30;
- (2) reconsider and withdraw the rejection of the claims; and
- (3) pass claims 28-30 and 52-69 to allowance.

If the Examiner is of contrary view, the Examiner is requested to contact the undersigned attorney at 215-568-3100.

Respectfully submitted,



Jeffrey H. Rosedale
Registration No. 46,018

Date: October 28, 2004

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



US006326358B1

(12) **United States Patent**
Manoharan

(10) **Patent No.:** **US 6,326,358 B1**
(45) **Date of Patent:** ***Dec. 4, 2001**

(54) **CARBOHYDRATE OR 2'-MODIFIED OLIGONUCLEOTIDES HAVING ALTERNATING INTERNUCLEOSIDE LINKAGES**

(75) Inventor: **Muthiah Manoharan**, Carlsbad, CA (US)

(73) Assignee: **ISIS Pharmaceuticals, Inc.**, Carlsbad, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/349,007**

(22) Filed: **Jul. 7, 1999**

Related U.S. Application Data

(63) Continuation-in-part of application No. 09/115,025, filed on Jul. 14, 1998.

(51) Int. Cl.⁷ **A61K 31/712; A61K 31/7125; C07H 21/00; C12N 5/00; C12Q 1/68**

(52) U.S. Cl. **514/44; 435/6; 435/375; 536/24.3; 536/24.5**

(58) Field of Search **435/6, 375; 514/44; 536/24.3, 24.31, 24.5**

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,687,808	8/1972	Merigan et al.	195/28
4,689,320	8/1987	Kaji	514/44
4,806,463	2/1989	Goodchild et al.	435/5
5,004,810	4/1991	Draper	536/27
5,166,195	11/1992	Ecker	514/44
5,194,428	3/1993	Agrawal et al.	514/44
5,212,295	5/1993	Cook	536/26.7
5,242,906	9/1993	Pagano et al.	514/44
5,248,670	9/1993	Draper et al.	514/44
5,264,423	11/1993	Cohen et al.	
5,442,049	8/1995	Anderson et al.	536/24.5
5,457,189	10/1995	Crooke et al.	536/24.5
5,514,577	5/1996	Draper et al.	435/238
5,514,788	5/1996	Bennett et al.	536/23.1
5,523,389	6/1996	Ecker et al.	536/23.1
5,580,767	12/1996	Cowsert et al.	435/172.3
5,582,972	12/1996	Lima et al.	435/6
5,582,986	12/1996	Monia et al.	435/6
5,587,361	12/1996	Cook et al.	514/44
5,591,600	1/1997	Ecker	435/69.1
5,591,623	1/1997	Bennett et al.	435/240.2
5,591,720	1/1997	Anderson et al.	514/44
5,599,797	2/1997	Cook et al.	514/44
5,607,923	3/1997	Cook et al.	514/44
5,620,963	4/1997	Cook et al.	514/44
5,658,891	8/1997	Draper et al.	514/44
5,661,134	8/1997	Cook et al.	514/44
5,670,633	9/1997	Cook et al.	536/23.1
5,681,747	10/1997	Boggs et al.	435/375
5,681,944	10/1997	Crooke et al.	536/24.5

5,691,461	11/1997	Ecker et al.	536/24.32
5,877,309	3/1999	Dean et al.	536/24.5
5,955,443	9/1999	Bennett et al.	514/44
5,985,558	11/1999	Dean et al.	435/6

FOREIGN PATENT DOCUMENTS

WO 93/07883	4/1993	(WO)	
WO 93/18052	9/1993	(WO)	
WO 94/08003	4/1994	(WO)	
WO 95/13934			
A1	5/1995	(WO)	

OTHER PUBLICATIONS

Offensperger et al, Antisense Therapy of Hepatitis B Virus Infection, *Methods in Molecular Medicine: Antisense Therapeutics*, pp. 143-158.*

Offensperger et al, In Vivo Inhibition of Duck Hepatitis B Virus Replication and Gene Expression by Phosphorothioate Modified Antisense Oligodeoxynucleotides, 1993, *The EMBO Journal*, vol. 12, No. 3, pp. 1257-1262.*

Oberbauer et al, In Vivo Suppression of the Renal Na/P1 cotransporter by Antisense Oligonucleotides, May 1996, *Physiology*, vol. 93, pp. 4903-4906.*

Neurath et al, Local Administration of Antisense Phosphorothioate Oligonucleotides to the p65 subunit of NF- κ B Abrogates established experimental colitis in mice, *Nature Medicine*, vol. 2, No. 9.*

Monia et al, Sequence-Specific Antitumor activity of a Phosphorothioate Oligodeoxynucleotide targeted to human C-raf Kinase supports an Antisense mechanism of action in vivo, Dec. 1996, *Pharmacology*, pp. 15481-15484.*

Monia et al, Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase, Jun. 1996, *Nature Medicine*, vol. 2, No. 6, pp. 668-674.*

Leonetti et al, Antitumor Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides on Human Melanoma Cells in Vitro and in Mice, Apr. 1996, *Journal of the National Cancer Institute*, vol. 88, No. 7, pp. 419-429.*

Kitajima et al, Ablation of Transplanted HTLV-I Tax-Transformed Tumors in Mice by Antisense Inhibition of NF- κ B, Dec. 1992, *Science*, vol. 258, pp. 1192-1196.*

Simons et al, Antisense c-myc oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo, Sep. 1992, *Nature*, vol. 359, pp. 67-70.*

Cucco et al, In Vitro and In Vivo Reversal of Multidrug Resistance in a Human Leukemia-resistant Cell Line by mdr1 Antisense Oligodeoxynucleotides, Dec. 1996, *Cancer Research*, vol. 56, pp. 4332-4337.*

Primary Examiner—Sean McGarry

Assistant Examiner—Thomas G Larson

(74) *Attorney, Agent, or Firm*—Woodcock Washburn Kurtz Mackiewicz & Norris LLP

(57) **ABSTRACT**

Novel compounds that mimic and/or modulate the activity of wild-type nucleic acids. In general, the compounds are oligonucleotides which contain at least one region of 2'-modified nucleosides connected by alternating phosphodiester and phosphorothioate linkages.

27 Claims, 3 Drawing Sheets

OTHER PUBLICATIONS

- Del Bufalo et al, Effect of cisplatin and c-myc antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo, 1996, *British Journal of Cancer*.*
- Antisense '97: A roundtable on the state of the industry. *Nature Biotechnol.* 15: 519-524 (6/97).*
- Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. *Proc. Natl. Acad. Sci. USA* 93: 3161-3163 (4/96).*
- Gura. Antisense has growing pains. *Science* 270: 575-577 (10/95).*
- Rojanasakul. Antisense oligonucleotide therapeutics: Drug delivery and targeting. *Adv. Drug Delivery Rev.* 18: 115-131 (1996).*
- Stull et al. Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects. *Pharm. Res.* 12: 465-483 (4/95).*
- Jen et al. Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies. *Stem Cells* 18 (2000): 307-319.*
- Albert, P.R. et al., "Antisense knockouts: molecular scalpels for the dissection of signal transduction", *Trends Pharmacol. Sci.*, 1994, 15, 250-254.
- Ausubel, F.M. et al., (eds.), *Current Protocols in Molecular Biology*, Current Publications, 1993.
- Baker, B.F. et al., "2'-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells", *J. Biol. Chem.*, 1997, 272, 11994-12000.
- Berkow et al. (eds.), *The Merck Manual of Diagnosis and Therapy*, 15th Edition, Rahway, N.J., 1987, 2301-2310.
- Berkow et al. (eds.), *The Merck Manual of Diagnosis and Therapy*, 15th Edition, Rahway, N.J., 1987, 2263-2277.
- Berkow et al. (eds.), *The Merck Manual of Diagnosis and Therapy*, 15th Edition, Rahway, N.J., 1987, 2283-2287.
- Berkow et al. (eds.), *The Merck Manual of Diagnosis and Therapy*, 15th Edition, Rahway, N.J., 1987, 2286-2292.
- Bernhard et al., "Direct Evidence Linking Expression of Matrix Metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells", *Proc. Natl. Acad. Sci. U.S.A.*, 1994, 91, 4293-4297.
- Birkedal-Hansen, "Proteolytic Remodeling of Extracellular Matrix," *Curr. Op. Cell Biol.*, 1995, 7, 728-735.
- Boggemeyer et al., "Borrelia burgdorferi Upregulates the Adhesion Molecules E-selectin, P-selectin, ICAM-1 and VCAM-1 on Mouse Endothelioma Cells in vitro," *Cell Adhes. Commun.*, 1994, 2, 145-157.
- Cook, P.D., "Medicinal chemistry of antisense oligonucleotides—future opportunities", *Anti-Cancer Drug Design*, 1991, 6, 585-607.
- Crooke, S.T. et al., "Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in mice", *J. Pharmacol. Exp. Therapeutics*, 1996, 277, 923-937.
- Crooke, S.T. et al., "Progress in Antisense Oligonucleotide Therapeutic", *Ann. Rev. Pharmacol. Toxicol.*, 1996, 36, 107-129.
- Dean, N.M. et al., "Inhibition of protein kinase C- α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides", *Proc. Natl. Acad. Sci.*, 1994, 91, 11762-11766.
- DeLisser et al., "Molecular and Functional Aspects of PECAM-1/CD31," *Immunol. Today*, 1994, 15, 490-494.
- Downward, "The ras Superfamily of Small GTP-binding proteins," *TIBS*, 15, 1990, 469-472.
- Englisch, U. et al., "Chemically Modified Oligonucleotides as Probes and Inhibitors", *Angew. Chem. Int. Ed. Eng.*, 1991, 30, 613-629.
- Griffiths, C.E.M. et al., "Keratinocyte Intercellular Adhesion Molecule-1 (ICAM-1) Expression Precedes Dermal T Lymphocyte Infiltration in Allergic Contact Dermatitis (*Rhus dermatitis*)", *Am. J. Pathology*, 1989, 135, 1045-1053.
- Gum et al., "Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor Binding Sites Including Closely Spaced PEA3/ets and AP-1 Sequences," *J. Biol. Chem.*, 1996, 271, 10672-10680.
- Hakugawa et al., "The Inhibitory Effect of Anti-Adhesion Molecule Antibodies on Eosinophil Infiltration in Cutaneous Late Phase Response in Balb/c Mice Sensitized with Ovalbumin (OVA)," *J. Dermatol.*, 1997, 24, 73-79.
- Hegemann, L. et al., "Biochemical Pharmacology of Protein Kinase C and its Relevance for Dermatology", *Pharmacology of the Skin*, Mukhtar, H. (ed.), CRC Press, Boca Raton, 1992, Ch.22, 357-268.
- Himelstein et al., "Proteases and Their Inhibitors in Invasion and Metastasis, Metalloproteinases in Tumor Progression: The Contribution of MMP-9," *Invasion Metastasis*, 1994-95, 14, 246-258.
- Ho, V.C. et al., "Treatment of severe lichen planus with cyclosporine", *J. Am. Acad. Dermatol.*, 1990, 22, 64-68.
- Hua et al., "Inhibition of Matrix Metalloproteinase 9 Expression by a Ribozyme Blocks Metastasis in a Rat Sarcoma Model System," *Cancer Res.*, 1996, 56, 5279-5284.
- Hurtenbach et al., "Prednisolone Reduces Experimental Arthritis and Inflammatory Tissue Destruction in Scid Mice Infected with *Borrelia burgdorferi*," *Int. J. Immunopharmacol.*, 1996, 18, 281-288.
- Kabanov, A. V., "A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells", *FEBS Letts.*, 1990, 259, 327-330.
- Katocs, A.S. et al., "Biological Testing", *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro (ed.), Mack Publishing Co., Easton, PA, 1990, Ch. 27, 484-494.
- Kerr et al., "TGF- β 1 Inhibition of Transin/Stromelysin Gene Expression Is Mediated Through a Fos Binding Sequence," *Cell*, 1990, 61, 267-278.
- Kerr et al., "Growth Factors Regulate Transin Gene Expression by c-fos-Dependent and c-fos-Independent Pathways," *Science*, 1988, 242, 1424-1427.
- Kroschwitz, J.I., "Polynucleotides", *Concise Encyclopedia of Polymer Science and Engineering*, 1990, John Wiley & Sons, New York, 858-859.
- Letsinger, R.L. et al., "Cholesteryl-conjugated oligonucleotides: Synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in cell culture", *Proc. Natl. Acad. Sci.*, 1989, 86, 6553-6556.
- Lisby, S. et al., "Intercellular adhesion molecule-1 (ICAM-1) expression correlated to inflammation", *Br. J. Dermatol.*, 1989, 120, 479-484.
- Litwin et al., "Novel Cytokine-independent Induction of Endothelial Adhesion Molecules Regulated by Platelet/Endothelial Cell Adhesion Molecule (CD31)," *The Journal of Cell Biology*, 1997, 139, 219-228.
- Manoharan, M. et al., "Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antisense Applications", *Bioorg. Med. Chem. Letts.*, 1993, 3, 2765-2770.

- Manoharan, M. et al., "Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides", *Annals NY Acad. Sciences*, 1992, 660, 306-309.
- Manoharan, M., *Antisense Research and Applications*, Crooke et al. (eds.), CRC Press, Boca Raton, 1993.
- Manoharan M. et al., "Cholic Acid-Oligonucleotide Conjugates for Antisense Applications", *Bioorganic Med. Chem. Letts.*, 1994, 4, 1053-1060.
- Manoharan, M. et al., "Lipidic Nucleic Acids", *Tetrahedron Letts.*, 1995, 36, 3651-3654.
- Manoharan M. et al., "Oligonucleotide Conjugates: Alteration of the Pharmacokinetic Properties of Antisense Agents", *Nucleosides and Nucleotides*, 1995, 14, 969-973.
- Martin, P., "Ein neuer Zugang zu 2'-O-Alkylribonucleosiden und Eigenschaften deren Oligonucleotide", *Helvetica Chimica Acta*, 1995, 78, 486-504 (English summary included).
- Meyer, R.B. et al., "Efficient, Specific Cross-Linking and Cleavage of DNA by Stable, Synthetic Complementary Oligodeoxynucleotides", *J. Am. Chem. Soc.*, 1989, 111, 8517-8519.
- Mishra, R.K. et al., "Improved leishmanicidal effect of phosphorothioate antisense oligonucleotides by LDL-mediated delivery", *Biochim. Et Biophysica*, 1995, 124, 229-237.
- Newman, "The Biology of PECAM-1," *J. Clin. Invest.*, 1997, 99, 3-7.
- Nies, A.S. et al., "Principles of Therapeutics", *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. (eds.), McGraw-Hill, New York, NY, 1996, Ch. 3, 43-62.
- Oberhauser, B. et al., "Effective incorporation of 2'-O-methyl-oligonucleotides into liposomes and enhanced cell association through modification with thiocholesterol", *Nucl. Acids Res.*, 1992, 20, 533-538.
- Regezi et al., "Vascular Adhesion Molecules in Oral Lichen Planus," *Oral Surg. Oral Med. Oral Pathol.*, 1996, 81, 682-690.
- Ruoslahti, "Fundamental Understandings: How Cancer Spreads," *Sci. Am.*, 1996, 72-77.
- Saison-Behmoaras, T. et al., "Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation", *EMBO J.*, 1991, 10, 1111-1118.
- Sambrook et al. (eds.), *Molecular Cloning: A Laboratory Manual*, Second Ed., Cold Spring Harbor Laboratory Press, 1989.
- Sanghvi, Y.S., "Heterocyclic Base Modifications in Nucleic acids and their Applications in Antisense Oligonucleotides", *Antisense Research and Applications*, 1993, Chapter 15, CRC Press, Boca Raton, 273-288.
- Secrist, J.A. et al., "Synthesis and Biological Activity of 4'-Thionucleosides", *10th International Roundtable: Nucleosides, Nucleotides and their Biological Applications*, Sep. 16-20 1992, Abstract 21, Park City, Utah, 40.
- Shea, R.G. et al., "Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates", *Nucl. Acids Res.*, 1990, 18, 3777-3783.
- Shiohara et al., "Fixed drug Eruption: Expression of Epidermal Keratinocyte Intercellular Adhesion Molecule-1 (ICAM-1)", *Arch. Dermatol.*, 1989, 125, 1371-1376.
- Smith-Jones, P.M. et al., "Antibody Labeling with Copper-67 Using the Bifunctional Macrocycle 4-[(1,4,8,11-Tetraazacyclotetradec-1-yl)methyl] benzoic Acid", *Bioconjugate Chem.*, 1991, 2, 415-421.
- Stetler-Stevenson et al., "Tumor Cell Interactions with the Extracellular Matrix During Invasion and Metastasis," *Annu. Rev. Cell Biol.*, Palade, G.E. et al. (eds.), 1993, 9, 541-573.
- Studer, M. et al., "One-Step Synthesis of Mono-N-substituted Azamacrocycles with a Carboxylic Group in the Side-Chain and their complexes with Cu²⁺ and Ni²⁺", *Helvetica Chimica Acta*, 1986, 69, 2081-2086.
- Svirmarchuk, F.P. et al., "Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups", *Biochimie*, 1993, 79, 49-54.
- U.S. Congress, Office of Technology Assessment, "The State-of-the-art in Genetic Screening", *Genetic Monitoring and Screening in the Workplace*, OTA-BA-455, U.S. Government Printing Office, Washington, D.C., 1990, Ch. 5, 77-99.
- Wahlestedt, C. et al., "Modulation of Anxiety and Neuropeptide Y-Y1 Receptors by Antisense Oligodeoxynucleotides", *Science*, 1993, 259, 528-531.
- Wahlestedt, C. et al., "Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions", *Nature*, 1993, 363, 260-263.
- Zhang, Z. et al., "Uptake of N-(4'-pyridoxyl)amines and release of amines by renal cells: A model for transporter-enhanced delivery of bioactive compounds", *Proc. Natl. Acad. Sci.*, 1991, 88, 10407-10410.
- Delgado, C. et al., "The Uses and Properties of PEG-Linked Proteins", *Crit. Rev. in Therapeutic Drug Carrier Sys.*, 1992, 9, 249-304.
- Hamm, M. L. et al., "Incorporation of 2'-Deoxy-2'-mercaptocytidine into Oligonucleotides via Phosphoramidite Chemistry," *J. Org. Chem.*, 1997, 62, 3415-3420.
- Ouchi, T. et al., "Synthesis and Antitumor Activity of Poly(Ethylene Glycol)s Linked to 5'-Fluorouracil via a Urethane or Urea Bond", *Drug Des. & Disc.*, 1992, 9, 93-105.
- Polushin, N. N. et al., "Synthesis of Oligonucleotides Containing 2'-Azido- and 2'-Amino-2'-deoxyuridine Using Phosphotriester Chemistry," *Tetra. Letts.*, 1996, 37(19), 3227-3230.
- Ravasio, N. et al., "Selective Hydrogenations Promoted by Copper Catalysts. 1. Chemoselectivity, Regioselectivity, and Stereoselectivity in the Hydrogenation of 3-Substituted Steroids", *J. Org. Chem.*, 1991, 56, 4329-4333.
- Thomson, J. B. et al., "Synthesis and Properties of Diuridine Phosphate Analogues Containing Thio and Amino Modifications," *J. Org. Chem.*, 1996, 61, 6273-6281.
- Furdon et al., "Rnase H Cleavage of RNA Hybridized to Oligonucleotides Containing Methylphosphonate, Phosphorothioate and Phosphodiester Bonds", *Nucleic Acids Research*, 1989, 17, pp. 9193-9204.
- Patil et al., "Synthesis & Properties of Oligothymidylate Analogues Containing Stereoregulated Phosphorothioate and Phosphodiester Linkages in an Alternating Manner", *Bioorganic & Medicinal Chem. Letters*, 1994, 4, pp. 2663-2666.

* cited by examiner






FIG. 1





1

CARBOHYDRATE OR 2'-MODIFIED OLIGONUCLEOTIDES HAVING ALTERNATING INTERNUCLEOSIDE LINKAGES

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Ser. No. 09/115,025, filed Jul. 14, 1998, the content of which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

This invention relates to the design and synthesis of nuclease resistant phosphorothioate oligonucleotides which are useful for therapeutics, diagnostics and as research reagents. Oligonucleotides are provided which contain at least one region of 2'-modified nucleosides connected by alternating phosphodiester and phosphorothioate linkages. Such compounds are resistant to nuclease degradation and are capable of modulating the activity of DNA and RNA.

BACKGROUND OF THE INVENTION

It is well known that most of the bodily states in multicellular organisms, including most disease states, are effected by proteins. Such proteins, either acting directly or through their enzymatic or other functions, contribute in major proportion to many diseases and regulatory functions in animals and man. For disease states, classical therapeutics has generally focused upon interactions with such proteins in efforts to moderate their disease-causing or disease-potentiating functions. In newer therapeutic approaches, modulation of the actual production of such proteins is desired. By interfering with the production of proteins, the maximum therapeutic effect can be obtained with minimal side effects. It is therefore a general object of such therapeutic approaches to interfere with or other-wise modulate gene expression, which would lead to undesired protein formation.

One method for inhibiting specific gene expression is with the use of oligonucleotides, especially oligonucleotides which are complementary to a specific target messenger RNA (mRNA) sequence. Several oligonucleotides are currently undergoing clinical trials for such use. Phosphorothioate oligonucleotides are presently being used as therapeutic agents in human clinical trials against various disease states, including use as antiviral agents.

In addition to such use as both indirect and direct regulators of proteins, oligonucleotides also have found use in diagnostic tests. Such diagnostic tests can be performed using biological fluids, tissues, intact cells or isolated cellular components. As with gene expression inhibition, diagnostic applications utilize the ability of oligonucleotides to hybridize with a complementary strand of nucleic acid. Hybridization is the sequence specific hydrogen bonding of oligomeric compounds via Watson-Crick and/or Hoogsteen base pairs to RNA or DNA. The bases of such base pairs are said to be complementary to one another.

Oligonucleotides are also widely used as research reagents. They are useful for understanding the function of many other biological molecules as well as in the preparation of other biological molecules. For example, the use of oligonucleotides as primers in PCR reactions has given rise to an expanding commercial industry. PCR has become a mainstay of commercial and research laboratories, and applications of PCR have multiplied. For example, PCR

2

technology now finds use in the fields of forensics, paleontology, evolutionary studies and genetic counseling. Commercialization has led to the development of kits which assist non-molecular biology-trained personnel in applying PCR. Oligonucleotides, both natural and synthetic, are employed as primers in such PCR technology.

Oligonucleotides are also used in other laboratory procedures. Several of these uses are described in common laboratory manuals such as *Molecular Cloning, A Laboratory Manual, Second Ed.*, J. Sambrook, et al., Eds., Cold Spring Harbor Laboratory Press, 1989; and *Current Protocols In Molecular Biology*, F. M. Ausubel, et al., Eds., Current Publications, 1993. Such uses include as synthetic oligonucleotide probes, in screening expression libraries with antibodies and oligomeric compounds, DNA sequencing, in vitro amplification of DNA by the polymerase chain reaction, and in site-directed mutagenesis of cloned DNA. See Book 2 of *Molecular Cloning, A Laboratory Manual*, supra. See also "DNA-protein interactions and The Polymerase Chain Reaction" in Vol. 2 of *Current Protocols In Molecular Biology*, supra.

A number of chemical modifications have been introduced into oligonucleotides to increase their usefulness in diagnostics, as research reagents and as therapeutic entities. Such modifications include those designed to increase binding to a target strand (i.e. increase melting temperatures, T_m), to assist in identification of an oligonucleotide or an oligonucleotide-target complex, to increase cell penetration, to stabilize against nucleases and other enzymes that degrade or interfere with the structure or activity of the oligonucleotides, to provide a mode of disruption (terminating event) once sequence-specifically bound to a target, and to improve the pharmacokinetic properties of the oligonucleotide.

The complementarity of oligonucleotides has been used for inhibition of a number of cellular targets. Complementary oligonucleotides are commonly described as being antisense oligonucleotides. Various reviews describing the results of these studies have been published including *Progress In Antisense Oligonucleotide Therapeutics*, Crooke, S. T. and Bennett, C. F., *Annu. Rev. Pharmacol. Toxicol.*, 1996, 36, 107-129. These oligonucleotides have proven to be powerful research tools and diagnostic agents. Certain oligonucleotides that have been shown to be efficacious are currently in human clinical trials.


The pharmacological activity of oligonucleotides, like other therapeutics, depends on a number of factors that influence the effective concentration of these agents at specific intracellular targets. One important factor for oligonucleotides is the stability of the species in the presence of nucleases. It is unlikely that unmodified, naturally-occurring oligonucleotides will be useful therapeutic agents because they are rapidly degraded by nucleases. The limitations of available methods for modification of the phosphate backbone of unmodified oligonucleotides have led to a continuing and long felt need for other modifications which provide resistance to nucleases and satisfactory hybridization properties for antisense oligonucleotide diagnostics and therapeutics.

SUMMARY OF THE INVENTION

The present invention provides compounds that mimic and/or modulate the activity of wild-type nucleic acids. In general, the compounds contain a selected sequence of covalently bound nucleosides which is specifically hybridizable with a targeted nucleoside sequence of single stranded or double stranded DNA or RNA.

3

In some preferred embodiments, compounds are provided that comprise a plurality of covalently-bound 2'-modified nucleosides having the formula:



wherein:


- each B is a nucleobase;
- one of X₁ or X₂ is O, and the other of X₁ or X₂ is S;
- each R₁, is, independently, H, hydroxyl, C₁-C₂₀ alkyl, C₃-C₂₀ alkenyl, C₂-C₂₀ alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;
- or R₁ is a group of formula Z-R₂₂-(R₂₃)_n;
- Z is O, S, NH, or N-R₂₂-(R₂₃)_n;
- R₂₂ is C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, or C₂-C₂₀ alkynyl;
- R₂₃ is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide,

4

polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

v is from 0 to about 10;

or R₁ has the formula:



y₁ is 0 or 1;


y₂ is independently 0 to 10;

y₃ is 1 to 10;

E is C₁-C₁₀ alkyl, N(Q₁)(Q₂) or N=C(Q₁)(Q₂);


each Q₁ and Q₂ is, independently, H, C₁-C₁₀ alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support; or Q₁ and Q₂, together, are joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;

or R¹ has one of formula I or II:



I

II



wherein

Z₀ is O, S, or NH;

q¹ is from 0 to 10;

q² is from 1 to 10;

q³ is 0 or 1;

q⁴ is 0, 1 or 2;

Z₄ is OM₁, SM₁, or N(M₁)₂;

each M₁ is, independently, H, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C(=NH)N(H)M₂, C(=O)N(H)M₂ or OC(=O)N(H)M₂;

M₂ is H or C₁-C₈ alkyl;

Z₁, Z₂ and Z₃ comprise a ring system having from about 4 to about 7 carbon atoms, or having from about 3 to about 6 carbon atoms and 1 or 2 hetero atoms wherein said hetero atoms are selected from oxygen, nitrogen and sulfur, and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic; and


Z₅ is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, N(Q₁)(Q₂), OQ₁, halo, SQ₁ or CN;

n is from 2 to 50; and


m is 0 or 1.

Also provided in accordance with the present invention are oligonucleotides having the Formula:

5



6


W¹ has the Formula:

wherein:

X₁ is S; X₂ is O; R₂ is H, a hydroxyl protecting group, or an oligonucleotide; R₃ is OH, an oligonucleotide, or a linker connected to a solid support; and the other constituent variables are as defined above.

In some preferred embodiments, R₂ is a phosphodiester-linked oligonucleotide or a phosphorothioate linked oligonucleotide. In further preferred embodiments, R₃ is a phosphodiester-linked oligonucleotide or a phosphorothioate linked oligonucleotide. In still further preferred embodiments, R₂ and R₃ are each a phosphodiester-linked oligonucleotide or a phosphorothioate linked oligonucleotide.


The present invention also provides compounds having the Formula:



wherein:

35

wherein one of X₁ or X₂ is O, and the other of X₁ or X₂ is S; and the other constituent variables are as defined above; W³ has the Formula:



7

wherein R_3 is OH, an oligonucleotide, or a linker connected to a solid support; and

W^2 is a plurality of covalently bound nucleosides linked by phosphodiester or phosphorothioate linkages. In some preferred embodiments, W^2 is a plurality of covalently bound 2'-deoxy nucleosides linked by phosphodiester or phosphorothioate linkages.

In some preferred embodiments of the compounds and methods described herein, R_1 is $-O-CH_2-CH_2-O-CH_3$.

In further preferred embodiments of the compounds and methods of the invention, n is about 5 to about 50, with 8 to about 30 being more preferred, 4 to about 15 being even more preferred, and 2 to about 10 being especially preferred.

In some preferred embodiments, R_2 is H, and R_3 is OH.

The present invention also provides methods for modulating the production or activity of a protein in an organism, and methods for treating an organism having a disease characterized by the undesired production of a protein. Such methods involve contacting the organism with one or more of the foregoing compounds.

Also provided are methods for assaying a nucleic acid comprising the step of contacting a solution suspected to contain the nucleic acid with at least one such compound.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the inhibition of ICAM-1 expression in HUVEC by compounds of the invention and control compounds.


FIG. 2 is a graph showing certain comparative pharmacokinetic data for IV plasma concentration verse time for an oligonucleotide of the invention and two reference oligonucleotides.

FIG. 3 is a graph showing total radioactivity tissue content following IV bolus administration of an oligonucleotide of the invention and two reference oligonucleotides each administered at a dose of 3 mg/kg.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides oligonucleotides that contain at least one region of 2'-modified nucleosides connected by alternating phosphodiester and phosphorothioate linkages. In some preferred embodiments, the compounds have the comprise a plurality of covalently-bound 2'-modified nucleosides having the formula:

8



wherein:

each B is a nucleobase;

one of X_1 or X_2 is O, and the other of X_1 or X_2 is S;

each R_1 is, independently, H, hydroxyl, C_1-C_{20} alkyl, C_3-C_{20} alkenyl, C_2-C_{20} alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;

or R_1 is a group of formula $Z-R_{22}-(R_{23})_v$;


Z is O, S, NH, or N- $R_{22}-(R_{23})_v$;

R_{22} is C_1-C_{20} alkyl, C_2-C_{20} alkenyl, or C_2-C_{20} alkynyl;

R_{23} is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

v is from 0 to about 10;

or R_1 has the formula:



9



y1 is 0 or 1;

y2 is independently 0 to 10;

y3 is 1 to 10;

E is C₁-C₁₀ alkyl, N(Q₁)(Q₂) or N=C(Q₁)(Q₂);

each Q₁ and Q₂ is, independently, H, C₁-C₁₀ alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support; or Q₁ and Q₂, together, are joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;

or R₁ has one of formula I or II:

wherein

Z_p is O, S, or NH;q₁ is from 0 to 10;q₂ is from 1 to 10;q₃ is 0 or 1;q₄ is, 0, 1 or 2;Z₄ is OM₁, SM₁, or N(M₁)₂;

each M₁ is, independently, H, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C(=NH)N(H)M₂, C(=O)N(H)M₂ or OC(=O)N(H)M₂;

M₂ is H or C₁-C₈ alkyl;

Z₁, Z₂ and Z₃ comprise a ring system having from about 4 to about 7 carbon atoms, or having from about 3 to about 6 carbon atoms and 1 or 2 hetero atoms wherein said hetero atoms are selected from oxygen, nitrogen and sulfur, and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic; and

Z₅ is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, N(Q₁)(Q₂), OQ₁, halo, SQ₁ or CN;

n is from 2 to 50; and

m is 0 or 1.

It is known that phosphorothioate linkages are essential for certain pharmacological properties of oligonucleotides, such as nuclease resistance. However, excessive numbers of phosphorothioate linkages are thought to create toxicity problems for drug compounds, for example by create some non-sequence specific side effects. It has been discovered that compounds represented by the formulas provided herein beneficially possess both improved nuclease resistance relative to uniform phosphodiester oligomers, and increased binding affinity relative to phosphorothioate oligomers. In addition, the oligonucleotides described herein may have reduced toxicity relative to uniform phosphorothioate oligonucleotides.

The addition of phosphodiester linkages to phosphorothioate oligonucleotides is expected to favorably alter the pharmacokinetics of the oligonucleotide (for example, with respect to urinary excretion, preferred distribution to kidney). The staggered phosphorothioate/phosphodiester linkages also will modulate the protein binding to plasma proteins (serum, albumin, etc.).


Further, phosphorothioate uptake has been proposed to occur by several mechanisms. One such mechanism that has

10

been proposed is receptor mediated endocytosis. A further proposed mechanism is a shuttling mechanism, in which phosphorothioate oligonucleotides will shuttle between proteins based on their relative affinities. Thus, controlling the number of phosphorothioate linkages present in an oligonucleotide, in accordance with the present invention, can be crucial for uptake, antisense activity, and pharmacokinetics of such oligonucleotides.

While not wishing to be bound by a particular mechanism, it is believed that oligonucleotides of the present invention which have possess at least one region of uniform phosphodiester and/or phosphorothioate linkages function by a RNAase H dependent mechanism, in which hybridization leads to cleavage of the duplex by RNAase H. It is also believed that oligonucleotides of the present invention which have a uniform alternating phosphodiester/phosphorothioate backbone (i.e., oligonucleotides in which the entire backbone, or substantially the entire backbone) is composed of alternating phosphodiester/phosphorothioate linkages) do not function by a RNAase H dependent mechanism, but rather primarily 13-15 by a translation arrest mechanism.

The plurality of covalently-bound 2'-modified nucleosides, can form the entire oligonucleotide, or a part thereof. Thus, the plurality of covalently-bound 2'-modified nucleosides can be located at the 3'-terminal portion of an oligonucleotide, the 5'-terminal portion of an oligonucleotide, or at any position in between. Thus, in some preferred embodiments of the invention, oligonucleotides are provided having the Formula:




wherein:

X₁ is S; X₂ is O; R₂ is H, a hydroxyl protecting group, or an oligonucleotide; R₃ is OH, an oligonucleotide, or a linker connected to a solid support; and the other constituent variables are as defined above.


In the formula above, R₂, R₃ or both can be a phosphodiester-linked oligonucleotide or a phosphorothioate linked oligonucleotide.

The present invention also provides compounds having the Formula:




11

wherein:

W¹ has the Formula:

wherein one of X₁ or X₂ is O, and the other of X₁ or X₂ is S; and the other constituent variables are as defined above;

W³ has the Formula:

wherein R₃ is OH, an oligonucleotide, or a linker connected to a solid support; and

12

W² is a plurality of covalently bound nucleosides linked by phosphodiester or phosphorothioate linkages. In some preferred embodiments, W² is a plurality of covalently bound 2'-deoxy nucleosides linked by phosphodiester or phosphorothioate linkages.

In some especially preferred embodiments of the compounds and methods described herein, the 2'-substituent represented by R₁ is a —O-ethyl-O-methyl ("MOE") group.

In some especially preferred embodiments, the region of alternating phosphodiester/phosphorothioate linkages occurs at least one terminal of the oligonucleotide. It is especially preferred that the terminal nucleotide of such region have a phosphorothioate linkage.

The compounds of the invention can have appended thereto any of a variety of molecular conjugate species that serve to facilitate uptake, targeting or efficacy of the oligonucleotide. Representative conjugate moieties include phospholipids, cholesterol, folic acid, vitamins, steroids, and their derivatives. Additional conjugate species include proteins, peptides, alkylators, lipophilic molecules, intercalators, cell receptor binding molecules, crosslinking agents, and other groups for modifying properties of oligomers which include RNA cleaving complexes, pyrenes, metal chelators, porphyrins, hybrid intercalator/ligands and photo-crosslinking agents. RNA cleavers include o-phenanthroline/Cu complexes and Ru(bipyridine)₃²⁺ complexes. The Ru(bipyridine)₃²⁺ complexes interact with nucleic acids and cleave nucleic acids photochemically. Metal chelators include EDTA, DTPA, and o-phenanthroline. Alkylators include compounds such as iodoacetamide. Porphyrins include porphine, its substituted forms, and metal complexes. Pyrenes include pyrene and other pyrene-based carboxylic acids that can be conjugated using protocols similar to those specified above.

The term phospholipid as used herein includes those compounds which upon hydrolysis yield phosphoric acid, an alcohol and one or more fatty acids. Representative examples of phospholipids include lecithin, cephalin and sphingomyelin.

As used in the present invention, groups that enhance the pharmacodynamic properties include groups that improve oligonucleotide uptake, enhance oligonucleotide resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligonucleotide uptake, distribution, metabolism or excretion.

For the purposes of this invention, the terms "reporter molecule" and "reporter enzyme" are inclusive of those molecules or enzymes that have physical or chemical properties that allow them to be identified in gels, fluids, whole cellular systems, broken cellular systems and the like utilizing physical properties such as spectroscopy, radioactivity, calorimetric assays, fluorescence, and specific binding. Particularly useful as reporter molecules are fluorophores, chromophores and radiolabel-containing moieties. Fluorophores are molecules detectable by fluorescence spectroscopy. Examples of preferred fluorophores are fluorescein and rhodamine dyes and acridines. There are numerous commercial available fluorophores including "Texas Red" and other like fluoresceins and rhodamines available for Molecular Probes, Eugene, OR. Chromophores are molecules capable of detection by visible or ultraviolet (UV-VIS) absorbance spectroscopy. Examples of chromophores are polynuclear aromatics such as anthracene, perylene, pyrene, rhodamine and chrysene. Radiolabel-containing moieties, as used herein, are molecules incorporating at least one radioactive atom, such as ³H or ¹⁴C, enabling detection thereby. Reporter enzymes may be detected directly or via their enzymatic products by any of the methods mentioned above. Particularly useful as reporter enzymes are alkaline phosphatase and horseradish peroxidase.

Steroid molecules according to the invention include those chemical compounds that contain a perhydro-1,2-cyclopentanophenanthrene ring system. Particularly useful as steroid molecules are the bile acids including cholic acid, deoxycholic acid and dehydrocholic acid; steroids including cortisone, digoxigenin, testosterone and cholesterol and cationic steroids such as cortisone having a trimethylaminomethyl hydrazide group attached via a double bond at the 3-position of the cortisone ring (3-trimethylaminomethylhydrazido cortisone).

Proteins and peptides are utilized in their usual sense as polymers of amino acids. Normally peptides comprise such polymers that contain a smaller number of amino acids per unit molecule than do the proteins. Particularly useful as peptides and proteins are sequence-specific peptides and proteins including phosphodiesterases, peroxidases, phosphatases and nucleases. Such peptides and proteins include, but are not limited to, SV40 peptide, RNase A, RNase H and Staphylococcal nuclease.

Lipophilic molecules include naturally-occurring and synthetic aromatic and non-aromatic moieties such as fatty acids, esters and alcohols, other lipid molecules, cage structures such as adamantane and buckminsterfullerenes, and aromatic hydrocarbons such as benzene, perylene, phenanthrene, anthracene, naphthalene, pyrene, chrysene, and naphthacene. Particularly useful as lipophilic molecules are alicyclic hydrocarbons, saturated and unsaturated fatty acids, waxes, terpenes and polycyclic hydrocarbons including adamantane and buckminsterfullerenes.

Alkylators according to the invention are moieties that can effect attachment of electrophilic groups to targeted molecular structures. Representative alkylators are disclosed by Meyer, et al., *J. Am. Chem. Soc.* 1989, 111, 8517.

Intercalators are polycyclic aromatic moieties that can insert between adjacent base pairs without affecting normal Watson-Crick base pairing, and include hybrid intercalator/ligands such as the photonuclease/intercalator ligand 6-[[[9-[[6-(4-nitrobenzamido)hexyl]amino]acridin-4-yl]carbonyl]amino]hexanoylpentafluorophenyl ester. This compound has two noteworthy features: an acridine moiety that is an intercalator and a p-nitrobenzamido group that is a photonuclease. Other representative intercalators are disclosed by Manoharan, M., *Antisense Research and Applications*, Crooke and Lebleu, eds., CRC Press, Boca Raton, 1993.

Cell receptor binding molecules according to the invention are vitamins and carbohydrate moieties for which specific receptors exist within a cell. Representative cell receptor binding molecules are disclosed by Application Serial No. PCT/US92/09196, filed Oct. 23, 1992, the contents of which are incorporated herein by reference.

Crosslinking agents are moieties that can effect intrastand or interstrand covalent binding of RNA and/or DNA, and include photo-crosslinking agents. Examples of photo-crosslinking agents include aryl azides such as N-hydroxysuccinimidyl-4-azidobenzoate (HSAB) and N-succinimidyl-6-(4'-azido-2'-nitrophenylamino)hexanoate (SANPAH). Aryl azides conjugated to oligomers will effect crosslinking with nucleic acids and proteins upon irradiation. Other representative crosslinking agents are disclosed in International Patent Application Serial No. PCT/US93/02059, filed Mar. 5, 1993, which is incorporated herein by reference.

Useful crown amines are disclosed by Studer, et al., *Helv. Chim. Acta* 1986, 69, 2081 and Smith-Jones, et al., *Bioconjugate Chem.* 1991, 2, 415.

Vitamins according to the invention generally can be classified as water soluble or lipid soluble. Water soluble vitamins include thiamine, riboflavin, nicotinic acid or niacin, the vitamin B₆ pyridoxal group, pantothenic acid, biotin, folic acid, the B₁₂ cobalamin coenzymes, inositol, choline and ascorbic acid. Lipid soluble vitamins include the

vitamin A family, vitamin D, the vitamin E tocopherol family and vitamin K (and phytols). The vitamin A family, including retinoic acid and retinol, are absorbed and transported to target tissues through their interaction with specific proteins such as cytosol retinol-binding protein type II (CRBP-II), Retinol-binding protein (RBP), and cellular retinol-binding protein (CRBP). These proteins, which have been found in various parts of the human body, have molecular weights of approximately 15 kD. They have specific interactions with compounds of the vitamin A family, especially, retinoic acid and retinol.

The vitamin A family of compounds can be attached to oligomers of the invention via acid or alcohol functionalities found in the various family members. For example, conjugation of an N-hydroxysuccinimide ester of an acid moiety of retinoic acid to an amine function of a pendant group of the oligomer results in linkage of the vitamin A compound to the oligomer, via an amide bond. In similar fashion, standard esterification chemistries may be used to attach the acid moiety of the retinoic acid group to a 4'-oxygen of a compound of the invention, or to a hydroxyl function of a pendant group thereof.

α -Tocopherol (vitamin E) and other tocopherols (beta through zeta) can be similarly conjugated to oligomers also to enhance uptake due to their lipophilic character. The lipophilic vitamin, vitamin D, and its ergosterol precursors can be conjugated to oligomers through their hydroxyl groups by first activating the hydroxyl groups by forming, for example, hemisuccinate esters. Conjugation then is effected, as for instance, to an aminolinker pendant from the oligomer, or through other suitable functional groups described herein. Other vitamins that can be conjugated to oligomers through hydroxyl groups on the vitamins include thiamine, riboflavin, pyridoxine, pyridoxamine, pyridoxal, deoxypyridoxine. Lipid soluble vitamin K's and related quinone-containing compounds can be conjugated via carbonyl groups on the quinone ring. The phytol moiety of vitamin K may also serve to enhance binding of the oligomers to cells.

Pyridoxal phosphate is the coenzyme form of Vitamin B₆. Vitamin B₆ is also known as pyridoxine. Pyridoxal has specific B₆-binding proteins. The role of these proteins in pyridoxal transport has been studied by Zhang and McCormick, *Proc. Natl. Acad. Sci. USA*, 1991 88, 10407. Zhang and McCormick showed that a series of N-(4'-pyridoxyl)amines, in which several synthetic amines were conjugated at the 4'-position of pyridoxal, were able to enter cells by a process facilitated by the B₆ transporter. Zhang and McCormick also demonstrated the release of these synthetic amines within the cell. Other pyridoxal family members include pyridoxine, pyridoxamine, pyridoxal phosphate, and pyridoxic acid. Pyridoxic acid, niacin, pantothenic acid, biotin, folic acid and ascorbic acid can be conjugated to oligomers using N-hydroxysuccinimide esters as described above for retinoic acid.

The compounds of the invention are resistant to nuclease degradation and are capable of modulating the activity of DNA and RNA.

The term "nucleoside" as used in connection with this invention refers to a unit made up of a heterocyclic base and its sugar. The term "nucleotide" refers to a nucleoside having a phosphate group on its 3' or 5' sugar hydroxyl group.

As used herein, the term "oligonucleotide" is intended to include both naturally occurring and non-naturally occurring (i.e., "synthetic") oligomers of linked nucleosides. Although such linkages generally are between the 3' carbon of one nucleoside and the 5' carbon of a second nucleoside (i.e., 3'-5' linkages), other linkages (such as 2'-5' linkages) can be formed.

Naturally occurring oligonucleotides are those which occur in nature; for example ribose and deoxyribose phos-

15

phodiester oligonucleotides having adenine, guanine, cytosine, thymine and uracil nucleobases. As used herein, non-naturally occurring oligonucleotides are oligonucleotides that contain modified sugar, internucleoside linkage and/or nucleobase moieties. Such oligonucleotide analogs are typically structurally distinguishable from, yet functionally interchangeable with, naturally occurring or synthetic wild type oligonucleotides. Thus, non-naturally occurring oligonucleotides include all such structures which function effectively to mimic the structure and/or function of a desired RNA or DNA strand, for example, by hybridizing to a target.

Representative nucleobases include adenine, guanine, cytosine, uridine, and thymine, as well as other non-naturally occurring and natural nucleobases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halo uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo uracil), 4-thiouracil, 8-halo, oxa, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine. Further naturally and non naturally occurring nucleobases include those disclosed in U.S. Pat. No. 3,687,808 (Merigan, et al.), in chapter 15 by Sanghvi, in *Antisense Research and Application*, Ed. S. T. Crooke and B. Lebleu, CRC Press, 1993, in Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613-722 (see especially pages 622 and 623, and in the *Concise Encyclopedia of Polymer Science and Engineering*, J. I. Kroschwitz Ed., John Wiley & Sons, 1990, pages 858-859, Cook, *Anti-Cancer Drug Design* 1991, 6, 585-607, each of which are hereby incorporated by reference in their entirety). The term "nucleosidic base" is further intended to include heterocyclic compounds that can serve as like nucleosidic bases including certain "universal bases" that are not nucleosidic bases in the most classical sense but serve as nucleosidic bases. Especially mentioned as a universal base is 3-nitropyrrole.

As used herein the term "2'-substituent group" denotes groups attached to the 2' position of the ribosyl moiety, with or without an oxygen atom.

Preferred 2'-substituent groups described herein are represented in the compounds described herein by the variable R_1 , which can be independently, H, hydroxyl, C_1 - C_{20} alkyl, C_3 - C_{20} alkenyl, C_2 - C_{20} alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;

or R_1 is a group of formula $Z-R_{22}-(R_{23})_v$;

Z is O, S, NH, or $N-R_{22}-(R_{23})_v$;


R_{22} is C_1 - C_{20} alkyl, C_2 - C_{20} alkenyl, or C_2 - C_{20} alkynyl;

R_{23} is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

16

v is from 0 to about 10;

or R_1 has the formula:



$y1$ is 0 or 1;



$y2$ is independently 0 to 10;

$y3$ is 1 to 10;

E is C_1 - C_{10} alkyl, $N(Q_1)(Q_2)$ or $N=C(Q_1)(Q_2)$;

each Q_1 and Q_2 is, independently, H, C_1 - C_{10} alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support; or Q_1 and Q_2 , together, are joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;

or R_1 has one of formula I or II:



wherein

Z_0 is O, S, or NH;

q_1 is from 0 to 10;

q_2 is from 1 to 10;

q_3 is 0 or 1;

q_4 is 0, 1 or 2;

Z_4 is OM_1 , SM_1 , or $N(M_1)_2$;

each M_1 is, independently, H, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, $C(=NH)N(H)M_2$, $C(=O)N(H)M_2$ or $OC(=O)N(H)M_2$;

M_2 is H or C_1 - C_8 alkyl;

Z_1 , Z_2 and Z_3 comprise a ring system having from about 4 to about 7 carbon atoms, or having from about 3 to about 6 carbon atoms and 1 or 2 hetero atoms wherein said hetero atoms are selected from oxygen, nitrogen and sulfur, and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic; and

Z_5 is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, $N(Q_1)(Q_2)$, OQ_1 , halo, SQ_1 or CN .

Representative 2'-O— sugar substituents of formula are disclosed in U.S. patent application Ser. No.: 09/130,973, filed Aug. 7, 1998, entitled Capped 2'-Oxyethoxy Oligonucleotides, hereby incorporated by reference in its entirety.

Representative cyclic 2'-O— sugar substituents of formula II are disclosed in U.S. patent application Ser. No.: 09/123,108, filed Jul. 27, 1998, entitled RNA Targeted 2'-Modified Oligonucleotides that are Conformationally Preorganized, hereby incorporated by reference in its entirety.

One particularly preferred group includes 2'-methoxyethoxy [2'-O— $CH_2CH_2OCH_3$, also known as 2'-O-(2-methoxyethyl) or 2'-MOE] (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486), i.e., an alkoxyalkoxy group. A

further preferred modification includes 2'-dimethylaminoxyethoxy, i.e., a $O(CH_2)_2ON(CH_3)_2$ group, also known as 2'-DMAOE, as described in co-owned U.S. patent application Ser. No. 09/016,520, filed on Jan. 30, 1998, the contents of which are herein incorporated by reference. Other preferred modifications include 2'-methoxy (2'-O—CH₃) and 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂).

Further preferred 2'-sugar modifications amenable to the present invention include fluoro, O-alkyl, O-alkylamino, O-alkylalkoxy, protected O-alkylamino, O-alkylaminoalkyl, O-alkyl imidazole, and polyethers of the formula (O-alkyl)_m, where m is 1 to about 10. Preferred among these polyethers are linear and cyclic polyethylene glycols (PEGs), and (PEG)-containing groups, such as crown ethers and those which are disclosed by Ouchi, et al., *Drug Design and Discovery* 1992, 9, 93, Ravasio, et al., *J. Org. Chem.* 1991, 56, 4329, and Delgado et. al., *Critical Reviews in Therapeutic Drug Carrier Systems* 1992, 9, 249, each of which are hereby incorporated by reference in their entirety. Further sugar modifications are disclosed in Cook, P. D., *Anti-Cancer Drug Design*, 1991, 6, 585-607. Fluoro, O-alkyl, O-alkylamino, O-alkyl imidazole, O-alkylaminoalkyl, and alkyl amino substitution is described in U.S. patent application Ser. No. 08/398,901, filed Mar. 6, 1995, entitled *Oligomeric Compounds having Pyrimidine Nucleotide(s) with 2' and 5' Substitutions*, hereby incorporated by reference in its entirety.

Additional 2' sugar modifications amenable to the present invention include 2'-SR and 2'-NR₂ groups, where each R is, independently, hydrogen, a protecting group or substituted or unsubstituted alkyl, alkenyl, or alkynyl. 2'-SR nucleosides are disclosed in U.S. Pat. No. 5,670,633, issued Sep. 23, 1997, hereby incorporated by reference in its entirety. The incorporation of 2'-SR monomer synthons are disclosed by Hamm et al., *J. Org. Chem.*, 1997, 62, 3415-3420. 2'-NR₂ nucleosides are disclosed by Goettingen, M., *J. Org. Chem.*, 1996, 61, 6273-6281; and Polushin et al., *Tetrahedron Lett.*, 1996, 37, 3227-3230.

Sugars having O-substitutions on the ribosyl ring are also amenable to the present invention. Representative substitutions for ring O include S, CH₂, CHF, and CF₂, see, e.g., Secrist, et al., *Abstract 21, Program & Abstracts, Tenth International Roundtable, Nucleosides, Nucleotides and their Biological Applications*, Park City, Utah, Sep. 16-20, 1992, hereby incorporated by reference in its entirety. Additional modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide. For example, one additional modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533), an aliphatic chain, e.g., dodecanol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 111; Kabanov et al., *FEBS Lett.*, 1990, 259, 327; Svinarchuk et al., *Biochimie*, 1993, 75, 49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651), a palmityl moiety

(Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923).

As used herein, the term "alkyl" includes but is not limited to straight chain, branch chain, and cyclic unsaturated hydrocarbon groups including but not limited to methyl, ethyl, and isopropyl groups. Alkyl groups of the present invention may be substituted. Representative alkyl substituents are disclosed in U.S. Pat. No. 5,212,295, at column 12, lines 41-50, hereby incorporated by reference in its entirety.

Alkenyl groups according to the invention are to straight chain, branch chain, and cyclic hydrocarbon groups containing at least one carbon-carbon double bond, and alkynyl groups are to straight chain, branch chain, and cyclic hydrocarbon groups containing at least one carbon-carbon triply bond. Alkenyl and alkynyl groups of the present invention can be substituted.

Aryl groups are substituted and unsubstituted aromatic cyclic moieties including but not limited to phenyl, naphthyl, anthracyl, phenanthryl, pyrenyl, and xylyl groups. Alkaryl groups are those in which an aryl moiety links an alkyl moiety to a core structure, and aralkyl groups are those in which an alkyl moiety links an aryl moiety to a core structure.

In general, the term "hetero" denotes an atom other than carbon, preferably but not exclusively N, O, or S. Accordingly, the term "heterocycloalkyl" denotes an alkyl ring system having one or more heteroatoms (i.e., non-carbon atoms). Preferred heterocycloalkyl groups include, for example, morpholino groups. As used herein, the term "heterocycloalkenyl" denotes a ring system having one or more double bonds, and one or more heteroatoms. Preferred heterocycloalkenyl groups include, for example, pyrrolidino groups.

Oligonucleotides according to the present invention that are hybridizable to a target nucleic acid preferably comprise from about 5 to about 50 nucleosides. It is more preferred that such compounds comprise from about 8 to about nucleosides, with 15 to 25 nucleosides being particularly preferred. As used herein, a target nucleic acid is any nucleic acid that can hybridize with a complementary nucleic acid-like compound. Further in the context of this invention, "hybridization" shall mean hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding between complementary nucleobases. "Complementary" as used herein, refers to the capacity for precise pairing between two nucleobases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary" and "specifically hybridizable," as used herein, refer to precise pairing or sequence complementarity between a first and a second nucleic acid-like oligomers containing nucleoside subunits. For example, if a nucleobase at a certain position of the first nucleic acid is capable of hydrogen bonding with a nucleobase at the same position of the second nucleic acid, then the first nucleic acid and the second nucleic acid are considered to be complementary to each other at that position. The first and second nucleic acids are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleobases which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between a compound of the invention and a target RNA molecule. It is understood that an oligomeric compound of the invention need not be 100% complementary to its target RNA sequence to be specifically hybridizable. An oligomeric compound is specifically hybridizable when binding

of the oligomeric compound to the target RNA molecule interferes with the normal function of the target RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligomeric compound to non-target sequences under conditions in which specific binding is desired, i.e. under physiological conditions in the case of in vivo assays or therapeutic treatment, or in the case of in vitro assays, under conditions in which the assays are performed.

Phosphorothioate linkages in the oligonucleotides of the invention are prepared using standard phosphoramidite chemistry on, for example, an automated DNA synthesizer (e.g., Applied Biosystems model 380B) and oxidation with 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. Phosphorothioate linkages that have Sp configuration can be prepared generally according to the procedures described in U.S. Pat. Nos. 5,212,295, 5,587,361 and 5,599,797. In preferred embodiments, 2'-modified amidites are used to synthesize compounds of the invention according to standard phosphoramidite regimes. In especially preferred embodiments, the amidites have a 2'-methoxyethoxy ($-\text{O}-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_3$, "MOE") substituent.

As will be recognized, this invention concerns oligonucleotides that exhibit increased stability relative to their naturally occurring counterparts. Extracellular and intracellular nucleases generally do not recognize (and, therefore, do not bind to) the compounds of the invention. The modified internucleoside linkages of this invention preferably replace naturally-occurring phosphodiester-5'-methylene linkages to confer nuclease resistance.

The oligonucleotides of the invention can be used in diagnostics, therapeutics and as research reagents and kits. They can be used in pharmaceutical compositions by including a suitable pharmaceutically acceptable diluent or carrier. They further can be used for treating organisms having a disease characterized by the undesired production of a protein. The organism should be contacted with an oligonucleotide having a sequence that is capable of specifically hybridizing with a strand of nucleic acid coding for the undesirable protein. Treatments of this type can be practiced on a variety of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular eukaryotic organisms. Any organism that utilizes DNA-RNA transcription or RNA-protein translation as a fundamental part of its hereditary, metabolic or cellular control is susceptible to therapeutic and/or prophylactic treatment in accordance with the invention. Seemingly diverse organisms such as bacteria, yeast, protozoa, algae, all plants and all higher animal forms, including warm-blooded animals, can be treated. Further, each cell of multicellular eukaryotes can be treated, as they include both DNA-RNA transcription and RNA-protein translation as integral parts of their cellular activity. Furthermore, many of the organelles (e.g., mitochondria and chloroplasts) of eukaryotic cells also include transcription and translation mechanisms. Thus, single cells, cellular populations or organelles can also be included within the definition of organisms that can be treated with therapeutic or diagnostic oligonucleotides.

Some representative therapeutic indications and other uses for the compounds of the invention are as follows. One therapeutic indication of particular interest is psoriasis. Psoriasis is a common chronic and recurrent disease characterized by dry, well-circumscribed, silvery, scaling papules and plaques of various sizes. The disease varies in severity from a few lesions to widespread dermatosis with disabling arthritis or exfoliation. The ultimate cause of psoriasis is not known, but the thick scaling that occurs is probably due to increased epidermal cell proliferation (*The Merck Manual of Diagnosis and Therapy*, 15th Ed., pp. 2283-2285, Berkow et al., eds., Rahway, N.J., 1987). Inhibi-

tors of Protein Kinase C (PKC) have been shown to have both antiproliferative and anti-inflammatory effects in vitro. Some antipsoriasis drugs, such as cyclosporin A and anthralin, have been shown to inhibit PKC, and inhibition of PKC has been suggested as a therapeutic approach to the treatment of psoriasis (Hegemann, L. and G. Mahrle, *Pharmacology of the Skin*, H. Mukhtar, ed., pp. 357-368, CRC Press, Boca Raton, Fla., 1992). Antisense compounds targeted to Protein Kinase C (PKC) proteins are described in U.S. Pat. Nos. 5,620,963 to Cook et al. and 5,681,747 to Boggs et al.

Another type of therapeutic indication of interest is inflammatory disorders of the skin. These occur in a variety of forms including, for example, lichen planus, toxic epidermal necrolysis (TEN), erythema multiforme and the like (*The Merck Manual of Diagnosis and Therapy*, 15th Ed., pp. 2286-2292, Berkow et al., eds., Rahway, N.J., 1987). Expression of ICAM-1 has been associated with a variety of inflammatory skin disorders such as allergic contact dermatitis, fixed drug eruption, lichen planus and psoriasis (Ho et al., *J. Am. Acad. Dermatol.*, 1990, 22, 64; Griffiths et al., *Am. J. Pathology*, 1989, 135, 1045; Lisby et al., *Br. J. Dermatol.*, 1989, 120, 479; Shiohara et al., *Arch. Dermatol.*, 1989, 125, 1371; Regezi et al., *Oral Surg. Oral Med. Oral Pathol.*, 1996, 81, 682). Moreover, intraperitoneal administration of a monoclonal antibody to ICAM-1 decreases ovalbumin-induced eosinophil infiltration into skin in mice (Hakugawa et al., *J. Dermatol.*, 1997, 24, 73). Antisense compounds targeted to ICAM-1 are described in U.S. Pat. Nos. 5,514,788 and 5,591,623, and co-pending U.S. patent applications Ser. Nos. 09/009,490 and 9/062,416, Jan. 20, 1998 and Apr. 17, 1998, respectively, all to Bennett et al.

Other antisense targets for skin inflammatory disorders are VCAM-1 and PECAM-1. Intraperitoneal administration of a monoclonal antibody to VCAM-1 decreases ovalbumin-induced eosinophil infiltration into the skin of mice (Hakugawa et al., *J. Dermatol.*, 1997, 24, 73). Antisense compounds targeted to VCAM-1 are described in U.S. Pat. Nos. 5,514,788 and 5,591,623. PECAM-1 proteins are glycoproteins which are expressed on the surfaces of a variety of cell types (for reviews, see Newman, *J. Clin. Invest.*, 1997, 99, 3 and DeLisser et al., *Immunol. Today*, 1994, 15, 490). In addition to directly participating in cell-cell interactions, PECAM-1 apparently also regulates the activity and/or expression of other molecules involved in cellular interactions (Litwin et al., *J. Cell Biol.*, 1997, 139, 219) and is thus a key mediator of several cell:cell interactions. Antisense compounds targeted to PECAM-1 are described in co-pending U.S. patent application Ser. No. 09/044,506, filed Mar. 19, 1998, by Bennett et al.

Another type of therapeutic indication of interest for oligonucleotides encompasses a variety of cancers of the skin. Representative skin cancers include benign tumors (warts, moles and the like) and malignant tumors such as, for example, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, Kaposi's sarcoma and the like (*The Merck Manual of Diagnosis and Therapy*, 15th Ed., pp. 2301-2310, Berkow et al., eds., Rahway, N.J., 1987). A number of molecular targets involved in tumorigenesis, maintenance of the hyperproliferative state and metastasis are targeted to prevent or inhibit skin cancers, or to prevent their spread to other tissues.

The ras oncogenes are guanine-binding proteins that have been implicated in cancer by, e.g., the fact that activated ras oncogenes have been found in about 30% of human tumors generally; this figure approached 100% in carcinomas of the exocrine pancreas (for a review, see Downward, *Trends in Biol. Sci.*, 1990, 15, 469). Antisense compounds targeted to H-ras and K-ras are described in U.S. Pat. Nos. 5,582,972 to Lima et al., 5,582,986 to Monia et al. and 5,661,134 to Cook et al., and in published PCT application WO 94/08003.

Protein Kinase C (PKC) proteins have also been implicated in tumorigenesis. Antisense compounds targeted to Protein Kinase C (PKC) proteins are described in U.S. Pat. Nos. 5,620,963 to Cook et al. and 5,681,747 to Boggs et al. Also of interest are AP-1 subunits and JNK proteins, particularly in regard to their roles in tumorigenesis and metastasis. The process of metastasis involves a sequence of events wherein (1) a cancer cell detaches from its extracellular matrices, (2) the detached cancer cell migrates to another portion of an animal's body, often via the circulatory system, and (3) attaches to a distal and inappropriate extracellular matrix, thereby created a focus from which a secondary tumor can arise. Normal cells do not possess the ability to invade or metastasize and/or undergo apoptosis (programmed cell death) if such events occur (Ruoslahti, *Sci. Amer.*, 1996, 275, 72). However, many human tumors have elevated levels of activity of one or more matrix metalloproteinases (MMPs) (Stetler-Stevenson et al., *Annu. Rev. Cell Biol.*, 1993, 9, 541; Bernhard et al., *Proc. Natl. Acad. Sci. (U.S.A.)*, 1994, 91, 4293. The MMPs are a family of enzymes which have the ability to degrade components of the extracellular matrix (Birkedal-Hansen, *Current Op. Biol.*, 1995, 7, 728). In particular, one member of this family, matrix metalloproteinase-9 (MMP-9), is often found to be expressed only in tumors and other diseased tissues (Himelstein et al., *Invasion & Metastasis*, 1994, 14, 246).

Several studies have shown that regulation of the MMP-9 gene may be controlled by the AP-1 transcription factor (Kerr et al., *Science*, 1988, 242, 1242; Kerr et al., *Cell*, 1990, 61, 267; Gum et al., *J. Biol. Chem.*, 1996, 271, 10672; Hua et al., *Cancer Res.*, 1996, 56, 5279). Inhibition of AP-1 function has been shown to attenuate MMP-9 expression (U.S. patent application Ser. No. 08/837,201). AP-1 is a heterodimeric protein having two subunits, the gene products of fos and jun. Antisense compounds targeted to c-fos and c-jun are described in co-pending U.S. patent application Ser. No. 08/837,201, filed Mar. 14, 1997, by Dean et al.

Furthermore, AP-1 is itself activated in certain circumstances by phosphorylation of the Jun subunit at an amino-terminal position by Jun N-terminal kinases (JNKs). Thus, inhibition of one or more JNKs is expected to result in decreased AP-1 activity and, consequentially, reduced MMP expression. Antisense compounds targeted to JNKs are described in co-pending U.S. patent application Ser. No. 08/910,629, filed Aug. 13, 1997, by Dean et al.

Infectious diseases of the skin are caused by viral, bacterial or fungal agents. In the case of Lyme disease, the tick borne causative agent thereof, the spirochete *Borrelia burgdorferi*, up-regulates the expression of ICAM-1, VCAM-1 and ELAM-1 on endothelial cells in vitro (Boggemeyer et al., *Cell Adhes. Comm.*, 1994, 2, 145). Furthermore, it has been proposed that the mediation of the disease by the anti-inflammatory agent prednisolone is due in part to mediation of this up-regulation of adhesion molecules (Hurtenbach et al., *Int. J. Immunopharmac.*, 1996, 18, 281). Thus, potential targets for therapeutic mediation (or prevention) of Lyme disease include ICAM-1, VCAM-1 and ELAM-1 (supra).

Other infectious disease of the skin which are tractable to treatment using the compositions and methods of the invention include disorders resulting from infection by bacterial, viral or fungal agents (*The Merck Manual of Diagnosis and Therapy*, 15th Ed., pp. 2263-2277, Berkow et al., eds., Rahway, N.J., 1987).

With regards to infections of the skin caused by fungal agents, U.S. Pat. No. 5,691,461 provides antisense compounds for inhibiting the growth of *Candida albicans*.

With regards to infections of the skin caused by viral agents, U.S. Pat. Nos. 5,166,195, 5,523,389 and 5,591,600 provide oligonucleotide inhibitors of Human Immunodeficiency Virus (HIV). U.S. Pat. No. 5,004,810 provides oli-

gomers capable of hybridizing to herpes simplex virus Vmw65 mRNA and inhibiting its replication. U.S. Pat. Nos. 5,194,428 and 5,580,767 provide antisense compounds having antiviral activity against influenzavirus. U.S. Pat. No. 4,806,463 provides antisense compounds and methods using them to inhibit HTLV-III replication. U.S. Pat. Nos. 4,689,320, 5,442,049, 5,591,720 and 5,607,923 are directed to antisense compounds as antiviral agents specific to cytomegalovirus (CMV). U.S. Pat. No. 5,242,906 provides antisense compounds useful in the treatment of latent Epstein-Barr virus (EBV) infections. U.S. Pat. Nos. 5,248,670, 5,514,577 and 5,658,891 provide antisense compounds useful in the treatment of herpesvirus infections. U.S. Pat. Nos. 5,457,189 and 5,681,944 provide antisense compounds useful in the treatment of papillomavirus infections. The antisense compounds disclosed in these patents, which are herein incorporated by reference, may be used with the compositions of the invention to effect prophylactic, palliative or therapeutic relief from diseases caused or exacerbated by the indicated pathogenic agents.

Antisense oligonucleotides employed in the compositions of the present invention may also be used to determine the nature, function and potential relationship of various genetic components of the body to disease or body states in animals. Heretofore, the function of a gene has been chiefly examined by the construction of loss-of-function mutations in the gene (i.e., "knock-out" mutations) in an animal (e.g., a transgenic mouse). Such tasks are difficult, time-consuming and cannot be accomplished for genes essential to animal development since the "knock-out" mutation would produce a lethal phenotype. Moreover, the loss-of-function phenotype cannot be transiently introduced during a particular part of the animal's life cycle or disease state; the "knock-out" mutation is always present. "Antisense knockouts," that is, the selective modulation of expression of a gene by antisense oligonucleotides, rather than by direct genetic manipulation, overcomes these limitations (see, for example, Albert et al., *Trends in Pharmacological Sciences*, 1994, 15, 250). In addition, some genes produce a variety of mRNA transcripts as a result of processes such as alternative splicing; a "knock-out" mutation typically removes all forms of mRNA transcripts produced from such genes and thus cannot be used to examine the biological role of a particular mRNA transcript. Antisense oligonucleotides have been systemically administered to rats in order to study the role of the N-methyl-D-aspartate receptor in neuronal death, to mice in order to investigate the biological role of protein kinase C- α , and to rats in order to examine the role of the neuropeptide Y1 receptor in anxiety (Wahlestedt et al., *Nature*, 1993, 363:260; Dean et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1994, 91:11762; and Wahlestedt et al., *Science*, 1993, 259:528, respectively). In instances where complex families of related proteins are being investigated, "antisense knockouts" (i.e., inhibition of a gene by systemic administration of antisense oligonucleotides) may represent the most accurate means for examining a specific member of the family (see, generally, Albert et al., *Trends Pharmacol. Sci.*, 1994, 15:250). By providing compositions and methods for the simple non-parenteral delivery of oligonucleotides and other nucleic acids, the present invention overcomes these and other shortcomings.

The administration of therapeutic or pharmaceutical compositions comprising the oligonucleotides of the invention is believed to be within the skill of those in the art. In general, a patient in need of therapy or prophylaxis is administered a composition comprising a compound of the invention, commonly in a pharmaceutically acceptable carrier, in doses ranging from 0.01 μ g to 100 g per kg of body weight depending on the age of the patient and the severity of the disorder or disease state being treated. Dosing is dependent on severity and responsiveness of the disease state to be

treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution or prevention of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual antisense compounds, and can generally be estimated based on EC₅₀s found to be effective in vitro and in vivo animal models.

In the context of the invention, the term "treatment regimen" is meant to encompass therapeutic, palliative and prophylactic modalities of administration of one or more compositions of the invention. A particular treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease or disorder, its severity and the overall condition of the patient, and may extend from once daily to once every 20 years. Following treatment, the patient is monitored for changes in his/her condition and for alleviation of the symptoms of the disorder or disease state. The dosage of the composition may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disorder or disease state is observed, or if the disorder or disease state has been ablated.

An optimal dosing schedule is used to deliver a therapeutically effective amount of the oligonucleotide of the invention. The term "therapeutically effective amount," for the purposes of the invention, refers to the amount of oligonucleotide-containing pharmaceutical composition which is effective to achieve an intended purpose without undesirable side effects (such as toxicity, irritation or allergic response). Although individual needs may vary, determination of optimal ranges for effective amounts of pharmaceutical compositions is within the skill of the art. Human doses can be extrapolated from animal studies (Katocs et al., Chapter 27 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990). Generally, the dosage required to provide an effective amount of a pharmaceutical composition, which can be adjusted by one skilled in the art, will vary depending on the age, health, physical condition, weight, type and extent of the disease or disorder of the recipient, frequency of treatment, the nature of concurrent therapy (if any) and the nature and scope of the desired effect(s) (Nies et al., Chapter 3 In: *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, N.Y., 1996).

Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the bioactive agent is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years. For example, in the case of an individual known or suspected of being prone to an autoimmune or inflammatory condition, prophylactic effects may be achieved by administration of preventative doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years. In like fashion, an individual may be made less susceptible to an inflammatory condition that is expected to occur as a result of some medical treatment, e.g., graft versus host disease resulting from the transplantation of cells, tissue or an organ into the individual.

Prophylactic modalities for high risk individuals are also encompassed by the invention. As used herein, the term "high risk individual" is meant to refer to an individual for whom it has been determined, via, e.g., individual or family history or genetic testing, that there is a significantly higher

than normal probability of being susceptible to the onset or recurrence of a disease or disorder. For example, a subject animal could have a personal and/or family medical history that includes frequent occurrences of a particular disease or disorder. As another example, a subject animal could have had such a susceptibility determined by genetic screening according to techniques known in the art (see, e.g., U.S. Congress, Office of Technology Assessment, Chapter 5 In: *Genetic Monitoring and Screening in the Workplace*, OTA-BA-455, U.S. Government Printing Office, Washington, D.C., 1990, pages 75-99). As part of a treatment regimen for a high risk individual, the individual can be prophylactically treated to prevent the onset or recurrence of the disease or disorder. The term "prophylactically effective amount" is meant to refer to an amount of a pharmaceutical composition which produces an effect observed as the prevention of the onset or recurrence of a disease or disorder. Prophylactically effective amounts of a pharmaceutical composition are typically determined by the effect they have compared to the effect observed when a second pharmaceutical composition lacking the active agent is administered to a similarly situated individual.

For therapeutic use the oligonucleotide analog is administered to an animal suffering from a disease modulated by some protein. It is preferred to administer to patients suspected of suffering from such a disease an amount of oligonucleotide analog that is effective to reduce the symptomatology of that disease. One skilled in the art can determine optimum dosages and treatment schedules for such treatment regimens.

It is preferred that the RNA or DNA portion which is to be modulated be preselected to comprise that portion of DNA or RNA which codes for the protein whose formation or activity is to be modulated. The targeting portion of the composition to be employed is, thus, selected to be complementary to the preselected portion of DNA or RNA, that is to be an antisense oligonucleotide for that portion.

In accordance with one preferred embodiment of this invention, the compounds of the invention hybridize to HIV mRNA encoding the tat protein, or to the TAR region of HIV mRNA. In another preferred embodiment, the compounds mimic the secondary structure of the TAR region of HIV mRNA, and by doing so bind the tat protein. Other preferred compounds complementary sequences for herpes, papilloma and other viruses.

It is generally preferred to administer the therapeutic agents in accordance with this invention internally such as orally, intravenously, or intramuscularly. Other forms of administration, such as transdermally, topically, or intralethally may also be useful. Inclusion in suppositories may also be useful. Use of pharmacologically acceptable carriers is also preferred for some embodiments.

This invention is also directed to methods for the selective binding of RNA for research and diagnostic purposes. Such selective, strong binding is accomplished by interacting such RNA or DNA with compositions of the invention which are resistant to degradative nucleases and which hybridize more strongly and with greater fidelity than known oligonucleotides or oligonucleotide analogs.

Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are intended to be illustrative and not intended to be limiting.

EXAMPLE 1

Preparation of Oligonucleotides

Oligonucleotide Synthesis

Oligonucleotides were synthesized on a Perceptive Biosystems Expedite 8901 Nucleic Acid Synthesis System. The following summarizes the 1-μmol scale synthesis protocol.

Two synthesizers were used. One was set up to run the diester (P=O) protocol and the other to run the thioate (P=S) protocol. Trityl groups were removed with trichloroacetic acid (975 μ L over one minute) followed by an acetonitrile wash.

Phosphodiester (P=O) Protocol

All standard 2'-deoxy amidites (0.1M) were coupled twice per cycle (total coupling time was approximately 4 minutes). All novel (2'-modified) amidites were dissolved in dry acetonitrile (100 mg of amidite/1 mL acetonitrile) to give approximately 0.08–0.1 M solutions. Total coupling time was approximately 6 minutes (105 μ L of amidite delivered). 1-H-tetrazole in acetonitrile was used as the activating agent. Excess amidite was washed away with acetonitrile. (1S)-(+)-(10-camphorsulfonyl)oxaziridine (CSO, 1.0 g CSO/8.72 mL dry acetonitrile) was used to oxidize (4 minute wait step) delivering approximately 375 μ L of oxidizer.

Thioate (P=S) Protocol

The same amounts of amidites and reagents were delivered to the columns using the thioate protocol, except that the amount of oxidizer, 3H-1,2-benzodithiole-3-one-1,1-dioxide (Beaucage reagent, 3.4 g Beaucage reagent/200 mL acetonitrile), was 225 μ L (one minute wait step). In both protocols, unreacted functionalities were capped with a 50:50 mixture of tetrahydrofuran/acetic anhydride and tetrahydrofuran/pyridine/1-methyl imidazole. Trityl yields were followed by the trityl monitor during the duration of the synthesis. The final DMT group was left intact.

10 μ Mole Protocols

Approximately 300 mg CPG was used for each 10 μ mole synthesis. For the diester (P=O) couplings, the following protocol was used: Trityl group removal was done using 7.5 mLs of trichloroacetic acid. Coupling of both standard and novel amidites (0.8–0.1M) was achieved using a 23 minute coupling cycle with approximately 750 μ L of amidite delivered. Approximately 2.7 mL of oxidizer (CSO) was delivered over 3 minutes. The capping was done over 80 seconds with 1.8 mLs of a 50:50 mixture of tetrahydrofuran/acetic anhydride and tetrahydrofuran/pyridine/1-methyl imidazole. The thioate (P=S) couplings removed the trityl groups with 7.5 mLs of trichloroacetic acid. Couplings of standard 0.1M amidites were accomplished using 750 μ L of solution over 6.6 minutes. The novel amidite couplings were done using 750 μ L of 0.08–0.1M solutions, delivered over 23 minutes. Approximately 2.7 mL of oxidizer was delivered over 3

minutes. The capping was done over 80 seconds with 1.8 mLs of a 50:50 mixture of tetrahydrofuran/acetic anhydride and tetrahydrofuran/pyridine/1-methyl imidazole.

At 55° C., the 1 μ mole syntheses were deprotected and cleaved from the CPG in 1–2 mL 28.0–30% ammonium hydroxide (NH₄OH) for approximately 16 hours. The 10 μ mole synthesis CPG's was split into 2 vials for cleavage as described above. 5 mg NH₄OH was added to each vial.

Oligonucleotide Purification

After the deprotection step, the samples were filtered from CPG using Gelman 0.45 μ m nylon acrodisc syringe filters. Excess NH₄OH was evaporated away in a Savant AS160 automatic speed vac. The crude yield was measured on a Hewlett Packard 8452A Diode Array Spectrophotometer at 260 nm. Crude samples were then analyzed by mass spectrometry (MS) on a Hewlett Packard electrospray mass spectrometer. Trityl-on oligos were purified by reverse phase preparative high performance liquid chromatography (HPLC). HPLC conditions were as follows: Waters 600E with 991 detector; Waters Delta Pak C4 column (7.8x300mm); Solvent A: 50 mM triethylammonium acetate (TEA-Ac), pH 7.0; B: 100% acetonitrile; 2.5 mL/min flow rate; the gradient for 22592 and 25303: 5% B for first five minutes with linear increase in B to 80% during the next 55 minutes. The gradient for 18269: 5% B for first five minutes with linear increase in B to 60% during the next 55 minutes. Fractions containing the desired product were collected and the solvent was dried off in the speed vac. Oligos were detritylated in 80% acetic acid for approximately 60 minutes and lyophilized again. Free trityl and excess salt were removed by passing detritylated oligos through Sephadex G-25 (size exclusion chromatography) and collecting appropriate samples through a Pharmacia fraction collector. The solvent was again evaporated away in a speed vac. Purified oligos were then analyzed for purity by CGE, HPLC (flow rate: 1.5 mL/min; Waters Delta Pak C4 column, 3.9x300 mm), and MS. The final yield was determined by spectrophotometer at 260 nm.

³¹P NMR Analysis

³¹P NMR analysis indicated the right number of P=O and P=S linkages. The P=S chemical shifts are dispersed over 2–3 ppm due to the diastomeric nature of the P=S linkages.

The structures of the oligonucleotides, and their physical characteristics, are shown in Tables I and II, below:

TABLE I

Oligonucleotides containing Staggered PS/PO linkages					
Oligo #	ISIS#	Sequence (5'–3') ¹	Backbone	Chemistry	Target
1	18268 [SEQ ID NO:1]	5'–T ₈ C ^m ₈ T ₈ G ₈ A ₈ G ₈ T ₈ A ₈ G ₈ C ^m O	P=S/P=O	2'–O–MOE	Human
	staggered	A ₈ G ₈ A ₈ G ₈ G ₈ A ₈ G ₈ C ^m T ₈ C–3'			ICAM-1
	oligomer				
2	22592 [SEQ ID NO:2]	5'–A ₈ T ₈ G ₈ C ^m A ₈ T ₈ T ₈ C ₈ T ₈ G ₈ phd sC ₈ ^m C ₈ ^m C ₈ ^m C ₈ ^m	P=S/P=O	2'–O–MOE & 2'–H	mouse C-raf
	staggered	C ₈ ^m A ₈ C ₈ ^m G ₈ A–3'			
	gapmer				
3	25303 [SEQ ID NO:3]	5'–G ₈ C ₈ ^m C ₈ ^m C ₈ ^m A ₈ A ₈ G ₈ C ₈ ^m T ₈ G ₈ G ₈ C ^m O	P=S/P=O	2'–O–MOE & 2'–H	Human ICAM-1
	staggered	A ₈ T ₈ C ₈ ^m C ₈ ^m G ₈ T ₈ C ₈ ^m A–3'			
	hemimer				

¹All nucleosides in bold are 2'–O–MOE (2'–O–CH₂–CH₂–O–CH₃)

TABLE II

Physical characteristics of Oligonucleotides Containing Staggered PS/PO linkages					
ISIS #	Sequence (5'-3') ¹	Expected Mass (g)	Observed Mass (g)	HPLC Retn. Time (min) ²	#ODs Purified (@ 260 nm)
18268 [SEQ ID NO:1]	5'-TSC ^m ₀ T ₀ G ₀ A ₀ G ₀ T ₀ A ₀ G ₀ C ^m ₀ A ₀ G ₀ A ₀ G ₀ A ₀ G ₀ C ^m ₀ T ₀ C ^m -3'	7863	7865	21.00	1000
22592 [SEQ ID NO:2]	5'-A ₀ T ₀ G ₀ C ^m ₀ A ₀ T ₀ T ₀ C ^m ₀ T ₀ G ₀ C ^m ₀ C ^m ₀ C ^m ₀ C ^m ₀ A ₀ A ₀ G ₀ A ₀ -3'	7138	7123	22.00	136
25303 [SEQ ID NO:3]	5'-G ₀ C ^m ₀ A ₀ C ^m ₀ A ₀ A ₀ G ₀ C ^m ₀ T ₀ G ₀ A ₀ C ^m ₀ A ₀ T ₀ C ^m ₀ C ^m ₀ G ₀ T ₀ C ^m ₀ A ₀ -3'	7008	7006	22.00	1250

¹All nucleosides in bold are 2'-O-MOE

²Conditions: Waters 600E with detector 991; Waters C4 column (3.9x300mm); Solvent A: 50 mM TEA-Ac, pH 7.0; B: 100% acetonitrile; 1.5 mL/min. flow rate; Gradient: 5% B for first five minutes with linear increase in B to 60% during the next 55 minutes.

TEA-Ac, pH 7.0; B: 100% acetonitrile; 1.5 mL/min. flow rate; Gradient: 5% B for first five minutes with linear increase in B to 60% during the next 55 minutes.

EXAMPLE 2

T_m Analysis

T_m analysis of modified oligomers of the ICAM-1 series is shown in Table III below:

TABLE III

T _m Values of Human ICAM-1 Antisense Oligonucleotide ISIS 3067 and Analogs Against RNA Target 5'-TCT GAG TAG CAG AGG AGC TC-3' [SEQ. ID NO 4]		
Oligonucleotide	Modifications	T _m
ISIS 3067 [SEQ. ID NO 5]	P=S, 2'-deoxy DNA	50.1
ISIS 11910 [SEQ. ID NO 4]	P=O, 2'-deoxy DNA	58.4
ISIS 11159 [SEQ. ID NO 6]	P=S, 2'-MOE	79.2
ISIS 11158 [SEQ. ID NO 7]	P=O, 2'-MOE	86.6
ISIS 18268 [SEQ. ID NO 8]	P=O/P=S, STAGGERED 2'- MOE	84.0

It is significant to note from the above data that all 2'-MOE oligomers have higher binding affinity than 2'-H oligomers. In addition, in the series, ISIS 11159, 11158 and 18269 (the staggered oligomer) have binding affinity between the P=O and P=S oligomers, but the T_m loss is not significant (2.6°).

EXAMPLE 3

ICAM-1 Expression

Oligonucleotide Treatment of HUVECs

Cells were washed three times with Opti-MEM (Life Technologies, Inc.) prewarmed to 37° C. Oligonucleotides were premixed with 10 µg/ml Lipofectin (Life Technologies, Inc.) in Opti-MEM, serially diluted to the desired concentrations, and applied to washed cells. Basal and untreated (no oligonucleotide) control cells were also treated with Lipofectin. Cells were incubated for 4 h at 37° C., at which time the medium was removed and replaced with

standard growth medium with or without 5 mg/ml TNF-α (R & D Systems). Incubation at 37° C. was continued until the indicated times.

Quantitation of ICAM-1 Protein Expression By
Fluorescence-activated Cell Sorter

Cells were removed from plate surfaces by brief trypsinization with 0.25% trypsin in PBS. Trypsin activity was quenched with a solution of 2% bovine serum albumin and 0.2% sodium azide in PBS (+Mg/Ca). Cells were pelleted by centrifugation (1000 rpm, Beckman GPR centrifuge), resuspended in PBS, and stained with 3 µl/10⁵ cells of the ICAM-1 specific antibody, CD54-PE (Pharmingen). Antibodies were incubated with the cells for 30 min at 4° C. in the dark, under gently agitation. Cells were washed by centrifugation procedures and then resuspended in 0.3 ml of FACSFlow buffer (Becton Dickinson) with 0.5% formaldehyde (Polysciences). Expression of cell surface ICAM-1 was then determined by flow cytometry using a Becton Dickinson FACScan. Percentage of the control ICAM-1 expression was calculated as follows: [(oligonucleotide-treated ICAM-1 value)-(basal ICAM-1 value)/(non-treated ICAM-1 value)-(basal ICAM-1 value)]. (Baker, Brenda, et. al. 2'-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells, *The Journal of Biological Chemistry*, 272, 11994-12000, 1997.)

The oligonucleotides used in the study described above are shown in Table IV, below. Results are shown in Figure 1.

TABLE IV

Controlling P=S Linkages: ICAM-1 Activity with Alternating P=S/P=O Linkages in a Uniform 2'-modified Oligomer		
Isis #	Oligonucleotides Tested	
16952	TCTGAGTAGCAGAGGAGCTC	MOE, P=O [SEQ. ID. NO 9]
16953	GATCGCGTCGGACTATGAAG	Scrambled Control ^a [SEQ ID. NO 10]
15537	TCTGAGTAGCAGAGGAGCTC	MOE, P=S [SEQ. ID NO:11]

TABLE IV-continued

Controlling P=S Linkages: ICAM-1 Activity with Alternating P=S/P=O Linkages in a Uniform 2'-modified Oligomer		
Isis #	Oligonucleotides Tested	
16954	GATCGCGTCGGACTATGAAG	Scrambled Control [SEQ ID NO:12]
18268	TCTGAGTAGCAGAGGAGCTC*	MOE, P=S/P=O [SEQ ID NO:13]

C=5-methyl-C in all sequences (except C*)
*same base composition

The scrambled oligomers 16953 and 16954, which have the same base composition as the parent sequence, serve as controls.

It can be seen that the ICAM-1 expression data (Figure I) reveal that the staggered oligomer 18268 is more efficacious than both P=O oligomer (16952) and P=S oligomer (15537) in HUVEC cells. The oligomers are presumably working by a direct binding RNase H independent mechanism.

EXAMPLE 4

Pharmacokinetic Studies

Modulation of Protein Binding By P=S/P=O Oligonucleotide

Various pharmacokinetic parameters of oligonucleotides 11158, 11159 and 18268 of Example 2 were determined. The oligonucleotides were studied for various effects including modulation of protein binding and tissue distribution. The studies were performed in male Sprague-Dawley rats using I.V. bolus administration of ³H radio labeled oligonucleotides. The results are listed in Table V.

TABLE V

Comparative Plasma Pharmacokinetic Parameters			
PK Parameter	ISIS 11159	ISIS 18268	ISIS 11158
Cl _p (ml/min)	2.17	6.86	9.62
T _{1/2} distrib. (min)	22	12	8
Albumin Kd* (μM)	25	280	450

TABLE V-continued

Comparative Plasma Pharmacokinetic Parameters			
PK Parameter	ISIS 11159	ISIS 18268	ISIS 11158
Percent Excreted in Urine	5	13	48

The fully modified MOE P=O oligonucleotide, ISIS 11158, binds poorly to serum albumin protein and is distributed mainly to kidney and excreted in urine fast. The P=O/P=S alternating oligonucleotide, ISIS 18268, has higher plasma concentration than ISIS 11158 (MOE, P=O) but less than the MOE P=S oligonucleotide, ISIS 11159, as is seen in FIG. 2.

This also compares well with the serum albumin binding data seen in Table V.

The alternating fully modified MOE P=S/P=O oligonucleotide, ISIS 18268, bound to HSA with an affinity between that for the full P=S and the full P=O. This was measured by ultrafiltration techniques using fatty acid free albumin.

Changes in Tissue Distribution

The tissue distribution of the radio labeled oligonucleotides was examined in Sprague-Dawley rats following I.V. bolus administration. The results are shown in FIG. 3.

In these vivo pharmacokinetic studies, the P=S/P=O alternating oligonucleotide, ISIS 18268, exhibits reduced kidney distribution and increased overall tissue distribution compared to uniform P=O oligonucleotide, ISIS 11158. This also resulted in lower urinary excretion: 13% excreted in 6 hours compared to 48% in the same time period (6hrs) for P=O oligonucleotide. The P=S oligonucleotide, ISIS 11159, showed more compound in liver than both P=O and P=S/P=O oligonucleotides.

It is intended that each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification be herein incorporated by reference in their entirety.

Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

SEQUENCE LISTING

```

<160> NUMBER OF SEQ ID NOS: 13

<210> SEQ ID NO 1
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
linkages
<221> NAME/KEY: modified_base
<222> LOCATION: (2)..(20)
<223> OTHER INFORMATION: 2'-Methoxyethoxy
<223> OTHER INFORMATION: Description of Artificial Sequence: Novel
Sequence

<400> SEQUENCE: 1

```


-continued

tctgagtagc agaggagctc 20

<210> SEQ ID NO 2
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (1)..(20)
 <223> OTHER INFORMATION: Alternating phosphodiester/phosphorothioate linkages
 <221> NAME/KEY: modified_base
 <222> LOCATION: (1)..(6)
 <223> OTHER INFORMATION: 2'-Methoxyethoxy
 <221> NAME/KEY: modified_base
 <222> LOCATION: (15)..(20)
 <223> OTHER INFORMATION: 2'-Methoxyethoxy
 <223> OTHER INFORMATION: Description of Artificial Sequence: Novel Sequence

<400> SEQUENCE: 2

atgcattctg cccccaagga 20

<210> SEQ ID NO 3
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (1)..(20)
 <223> OTHER INFORMATION: Alternating phosphodiester/phosphorothioate linkages
 <221> NAME/KEY: modified_base
 <222> LOCATION: (13)..(20)
 <223> OTHER INFORMATION: 2'-Methoxyethoxy
 <223> OTHER INFORMATION: Description of Artificial Sequence: Novel Sequence

<400> SEQUENCE: 3

gccaagctg gcatccgtca 20

<210> SEQ ID NO 4
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Novel Sequence

<400> SEQUENCE: 4

tctgagtagc agaggagctc 20

<210> SEQ ID NO 5
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (1)..(20)
 <223> OTHER INFORMATION: All phosphorothioate linkages
 <223> OTHER INFORMATION: Description of Artificial Sequence: Novel Sequence

<400> SEQUENCE: 5

tctgagtagc agaggagctc 20

<210> SEQ ID NO 6
 <211> LENGTH: 20
 <212> TYPE: DNA

-continued

```

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: All phosphorothioate linkages
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: 2'-Methoxyethoxy
<223> OTHER INFORMATION: Description of Artificial Sequence: Novel
Sequence

<400> SEQUENCE: 6

tctgagtagc agaggagctc                20

<210> SEQ ID NO 7
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: 2'-Methoxyethoxy
<223> OTHER INFORMATION: Description of Artificial Sequence: Novel
Sequence

<400> SEQUENCE: 7

tctgagtagc agaggagctc                20

<210> SEQ ID NO 8
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
linkages
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: Staggered 2'-Methoxyethoxy
<223> OTHER INFORMATION: Description of Artificial Sequence: Novel
Sequence

<400> SEQUENCE: 8

tctgagtagc agaggagctc                20

<210> SEQ ID NO 9
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: 2'-Methoxyethoxy
<221> NAME/KEY: modified_base
<222> LOCATION: (2)
<223> OTHER INFORMATION: c=5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (10)
<223> OTHER INFORMATION: c=5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (18)
<223> OTHER INFORMATION: c=5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (20)
<223> OTHER INFORMATION: c=5-methyl
<223> OTHER INFORMATION: Description of Artificial Sequence: Novel
Sequence

<400> SEQUENCE: 9

tctgagtagc agaggagctc                20

```

-continued

```

<210> SEQ ID NO 10
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (4)
<223> OTHER INFORMATION: c-5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (6)
<223> OTHER INFORMATION: c-5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (9)
<223> OTHER INFORMATION: c-5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (13)
<223> OTHER INFORMATION: c-5-methyl
<223> OTHER INFORMATION: Description of Artificial Sequence: Novel
Sequence

```

```

<400> SEQUENCE: 10

```

```

gatcgcgctcg gactatgaag

```

20

```

<210> SEQ ID NO 11
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: 2'-Methoxyethoxy
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: All phosphorothioate linkages
<221> NAME/KEY: modified_base
<222> LOCATION: (2)
<223> OTHER INFORMATION: c-5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (10)
<223> OTHER INFORMATION: c-5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (18)
<223> OTHER INFORMATION: c-5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (20)
<223> OTHER INFORMATION: c-5-methyl
<223> OTHER INFORMATION: Description of Artificial Sequence: Novel
Sequence

```

```

<400> SEQUENCE: 11

```

```

tctgagtagc agaggagctc

```

20

```

<210> SEQ ID NO 12
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (4)
<223> OTHER INFORMATION: c-5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (6)
<223> OTHER INFORMATION: c-5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (9)
<223> OTHER INFORMATION: c-5-methyl
<221> NAME/KEY: modified_base
<222> LOCATION: (13)
<223> OTHER INFORMATION: c-5-methyl
<223> OTHER INFORMATION: Description of Artificial Sequence: Novel
Sequence

```

```

<400> SEQUENCE: 12

```

gattcgcgtcg gactatqaac

20

<400> SEQUENCE: 13

tctgaqtaqc agaggaqctc

20


The diagram illustrates a branched nucleic acid polymer. It features a main chain of nucleotides, where each nucleotide consists of a sugar moiety (B) attached to a phosphate group (P) which is further linked to a group (X₁). The sugar moiety also has a substituent (R₁). A side chain branches off from the main chain at a phosphate group, consisting of another nucleotide unit (sugar B, substituent R₁, phosphate P, and group X₁) linked to a third nucleotide unit (sugar B, substituent R₁, phosphate P, and group X₁). The main chain units are enclosed in large brackets with a subscript 'n', and the side chain units are enclosed in smaller brackets with a subscript 'm'.

30

10

45

50





each Q₁ and Q₂ is, independently, H, C₁-C₁₀ alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support; or Q₁ and Q₂, together, are joined in a nitrogen protecting

39

group or a ring structure that can include at least one additional heteroatom selected from N and O;

or R_1 has one of formula I or II:



wherein

Z_0 is O, S, or NH;

q_1 is from 0 to 10;

q_2 is from 1 to 10;

q_3 is 0 or 1;

q_4 is 0, 1 or 2;

Z_4 is OM_1 , SM_1 , or $N(M_1)_2$;

each M_1 is, independently, H, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, $C(=NH)N(H)M_2$, $C(=O)N(H)M_2$ or $OC(=O)N(H)M_2$;

M_2 is H or C_1 - C_8 alkyl;

Z_1 , Z_2 and Z_3 comprise a ring system having from about 4 to about 7 carbon atoms, or having from about 3 to about 6 carbon atoms and 1 or 2 hetero atoms wherein said hetero atoms are selected from oxygen, nitrogen and sulfur, and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic; and

Z_5 is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, $N(Q_1)(Q_2)$, OQ_1 , halo, SQ_1 or CN ;

n is from 2 to 50; and

m is 0 or 1.

2. The compound of claim 1 wherein R_1 is $-O-CH_2-CH_2-O-CH_3$.

3. The compound of claim 1 wherein n is about 5 to about 10.

4. The compound of claim 1 wherein n is about 8 to about 10.

5. The compound of claim 1 wherein n is about 4 to about 15.


6. The compound of claim 1 wherein n is about 2 to about 10.

7. A composition comprising a compound of claim 1 and an acceptable carrier.

8. A method of inhibiting the production or activity of a protein in an organism, comprising contacting said organism with a compound of claim 1.

40

9. An oligonucleotide having the Formula:



wherein:

each B is a nucleobase;

X_1 is S;

X_2 is O;

each R_1 is, independently, hydroxyl, C_1 - C_{20} alkyl, C_3 - C_{20} alkenyl, C_2 - C_{20} alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;

or R_1 is a group of formula $Z-R_{22}-(R_{23})_v$;


Z is O, S, NH, or $N-R_{22}-(R_{23})_v$;

R_{22} is C_1 - C_{20} alkyl, C_2 - C_{20} alkenyl, or C_2 - C_{20} alkynyl;

R_{23} is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether;



v is from 0 to about 10;

or R_1 has the formula:



41

y1 is 0 or 1;
 y2 is independently 0 to 10;
 y3 is 1 to 10;
 E is C₁-C₁₀ alkyl, N(Q₁)(Q₂) or N=C(Q₁)(Q₂);
 each Q₁ and Q₂ is, independently, H, C₁-C₁₀ alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support; or Q₁ and Q₂, together, are joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;
 or R₁ has one of formula I or II:




wherein

- Z₀ is O, S, or NH;
 q₁ is from 0 to 10;
 q₂ is from 1 to 10;
 q₃ is 0 or 1;
 q₄ is, 0, 1 or 2;
 Z₄ is OM₁, SM₁, or N(M₁)₂;
 each M₁ is, independently, H, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C(=NH)N(H)M₂, C(=O)N(H)M₂ or OC(=O)N(H)M₂;
 M₂ is H or C₁-C₈ alkyl;
 Z₁, Z₂ and Z₃ comprise a ring system having from about 4 to about 7 carbon atoms, or having from about 3 to about 6 carbon atoms and 1 or 2 hetero atoms wherein said hetero atoms are selected from oxygen, nitrogen and sulfur, and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic; and
 Z₅ is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, N(Q₁)(Q₂), OQ₁, halo, SQ₁ or CN;
 n is from 2 to 50; and
 m is 0 or 1;
 R₂ is H, a hydroxyl protecting group, or an oligonucleotide; and
 R₃ is OH, an oligonucleotide, or a linker connected to a solid support.
 10. The compound of claim 9 wherein R₁ is —O—CH₂—CH₂—O—CH₃.
 11. The compound of claim 10 wherein R₂ is H, and R₃ is OH.
 12. The compound of claim 10 wherein R₂ is a phosphodiester-linked oligonucleotide or a phosphorothioate linked oligonucleotide.
 13. The compound of claim 8 wherein R₃ is a phosphodiester-linked oligonucleotide or a phosphorothioate linked oligonucleotide.
 14. The compound of claim 10 wherein R₂ and R₃ are each a phosphodiester-linked oligonucleotide or a phosphorothioate linked oligonucleotide.
 15. A composition comprising a compound of claim 9 and an acceptable carrier.
 16. A method of inhibiting the production or activity of a protein in an organism, comprising contacting said organism with a compound of claim 9.


42

17. A compound having the Formula:



wherein:


W¹ has the Formula:





wherein:

- each B is a nucleobase;
 one of X₁ or X₂ is O, and the other of X₁ or X₂ is S;
 each R₁ is, independently, hydroxyl, C₁-C₂₀ alkyl, C₃-C₂₀ alkenyl, C₂-C₂₀ alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;
 or R₁ is a group of formula Z—R₂₂—(R₂₃)_v;
 Z is O, S, NH, or N—R₂₂—(R₂₃)_v;
 R₂₂ is C₁-C₂₀ alkyl, C₂-C₂₀ alkenyl, or C₂-C₂₀ alkynyl;
 R₂₃ is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether;
 v is from 0 to about 10;

43

or R₁ has the formula:y₁ is 0 or 1;y₂ is independently 0 to 10;y₃ is 1 to 10;E is C₁-C₁₀ alkyl, N(Q₁)(Q₂) or N=C(Q₁)(Q₂);

each Q₁ and Q₂ is, independently, H, C₁-C₁₀ alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support; or Q₁ and Q₂, together, are joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;



wherein

Z₀ is O, S, or NH;q¹ is from 0 to 10;q² is from 1 to 10;q³ is 0 or 1;q⁴ is, 0, 1 or 2;Z₄ is OM₁, SM₁, or N(M₁)₂;

each M₁ is, independently, H, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C(=NH)N(H)M₂, C(=O)N(H)M₂ or OC(=O)N(H)M₂;

M₂ is H or C₁-C₈ alkyl;

Z₁, Z₂ and Z₃ comprise a ring system having from about 4 to about 7 carbon atoms, or having from about 3 to about 6 carbon atoms and 1 or 2 hetero atoms wherein said hetero atoms are selected from oxygen, nitrogen and sulfur, and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic; and


Z₅ is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, N(Q₁)(Q₂), OQ₁, halo, SQ₁ or CN;

n is from 2 to 50; and

m is 0 or 1;

R₂ is H, a hydroxyl protecting group, or an oligonucleotide;

44

W³ has the Formula:

wherein R₃ is OH, an oligonucleotide, or a linker connected to a solid support; and

W² is a plurality of covalently bound nucleosides linked by phosphodiester or phosphorothioate linkages.

18. The compound of claim 17 wherein R₁ is —O—CH₂—CH₂—O—CH₃.

19. The compound of claim 18 wherein R₂ is H, and R₃ is OH.

20. The compound of claim 18 wherein n is about 5 to about 50.

21. The compound of claim 18 wherein n is about 8 to about 30.

22. The compound of claim 18 wherein n is about 4 to about 15.

23. The compound of claim 18 wherein n is 2 to about 10.

24. The compound of claim 18 wherein W² is a plurality of covalently bound nucleosides linked by phosphodiester linkages.

25. The compound of claim 18 wherein W² is a plurality of covalently bound nucleosides linked by phosphorothioate linkages.

26. A composition comprising a compound of claim 17 and an acceptable carrier.

27. A method of inhibiting the production or activity of a protein in an organism, comprising contacting said organism with a compound of claim 17.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 6,326,358 B1
DATED : December 4, 2001
INVENTOR(S) : Manoharan

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 37,

Line 35, please delete the formula that appears in Claim 1 and insert therefor



Signed and Sealed this

Thirteenth Day of July, 2004

JON W. DUDAS

Acting Director of the United States Patent and Trademark Office

The opinion in support of the decision being entered today was not written for publication and is not binding precedent of the Board.

Paper No. 26


UNITED STATES PATENT AND TRADEMARK OFFICE

**BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES**

Ex parte MUTHIAH MANOHARAN and
PHILLIP D. COOK

Appeal No. 2004-1394
Application No. 09/348,106

ON BRIEF



Before WINTERS, WILLIAM F. SMITH, and ADAMS, Administrative Patent Judges.

WILLIAM F. SMITH, Administrative Patent Judge.

DECISION ON APPEAL

This is an appeal under 35 U.S.C. § 134 from the examiner's final rejection of claims 1 through 10, all the claims pending in the application.

Claims 1, 9, and 10 are representative of the subject matter on appeal and read as follows:

1. An oligonucleotide comprising at least one 2-aminoadenosine nucleoside unit, at least one phosphorothioate internucleoside linkage, and at least one 5-substituted uridine or cytidine nucleoside unit.

9. A method of inhibiting expression of a gene comprising administering to cells or tissues the oligonucleotide of claim 1, said oligonucleotide having a sequence complementary to a portion of said gene.

COPY SENT TO CLIENT

ON 8/20/04

10. A method of treating a disease or condition, associated with the expression of a gene, in an animal, comprising administering to said animal the oligonucleotide of claim 1, said oligonucleotide having a sequence complementary to said gene, immune stimulation in said animal being reduced thereby.

The references relied upon by the examiner are:

- | | | |
|--------------------------------|-----------|---------------|
| Baracchini et al. (Baracchini) | 5,801,154 | Sep. 1, 1998 |
| Bennett et al. (Bennett '054) | 5,703,054 | Dec. 30, 1997 |
| Bennett et al. (Bennett '082) | 5,883,082 | Mar. 16, 1999 |
| Monia et al. (Monia '986) | 5,582,986 | Dec. 10, 1996 |
| Monia et al. (Monia '362) | 5,744,362 | Apr. 28, 1998 |
- James, "Toward Gene-Inhibition Therapy: A Review of Progress and Prospects in the Field of Antiviral Antisense Nucleic Acids and Ribozymes," Antiviral Chem. and Chemotherapy, Vol. 2, No. 4, pp. 191-214 (1991)
- Lamm et al. (Lamm), "Antisense Probes Containing 2-aminoadenosine Allow Efficient Depletion of U5 snRNP from HeLa Splicing Extracts," Nucleic Acids Res., Vol. 19, No. 12, pp. 3193-3198 (1991)
- Barabino et al. (Barabino), "Antisense Probes Targeted to an Internal Domain in U2 snRNP Specifically Inhibit the Second Step of Pre-mRNA Splicing," Nucleic Acids Res., Vol. 20, No. 17, pp. 4457-4464 (1992)
- Sanghvi et al. (Sanghvi), "Antisense Oligodeoxynucleotides: Synthesis, Biophysical and Biological Evaluation of Oligodeoxynucleotides Containing Modified Pyrimidines," Nucleic Acids Res., Vol. 21, No. 14, pp. 3197-3203 (1993)
- Gryaznov et al. (Gryaznov), "Stabilization of DNA:DNA and DNA:RNA Duplexes by Substitution of 2'-deoxyadenosine with 2'-deoxy-2-aminoadenosine," Tetrahedron Letters, Vol. 35, No. 16, pp. 2489-2492 (1994)
- Prosnyak et al. (Prosnyak), "Substitution of 2-Aminoadenine and 5-Methylcytosine for Adenine and Cytosine in Hybridization Probes Increases the Sensitivity of DNA Fingerprinting," Genomics, Vol. 21, pp. 490-494 (1994)
- Milner et al. (Milner), "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays," Nature Biotechnology, Vol. 15, pp. 537-541 (1997)
- Branch, "A Good Antisense Molecule is Hard to Find," Trends in Biochem. Sci., Vol. 23, pp. 45-50 (1998)

Buttinelli et al. (Buttinelli), "The Exocyclic Groups of DNA Modulate the Affinity and Positioning of the Histone Octamer," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 8544-8549 (1998)

Crooke, "Basic Principles of Antisense Therapeutics," Antisense Research and Application, Chapter 1, pp. 1-50 (Springer-Verlag 1998)

Claims 1, 3, and 4 stand rejected under 35 U.S.C. § 103(a). The examiner relies upon Monia '986, Prosnyak, Buttinelli, and Gryaznov as evidence of obviousness. Claim 2 is also rejected under this section of the statute with the examiner relying upon the previous four references and Sanghvi as evidence of obviousness. Claims 5 through 7 are rejected under this section of the statute with the examiner relying upon the previous five references and Lamm, Barabino, and Baracchini as evidence of obviousness. Claim 8 is rejected under this section of the statute with the examiner relying upon Monia '986, Prosnyak, Buttinelli, Gryaznov, Monia '362, Bennett '045, Bennett '082, Milner, and James as evidence of obviousness. Finally, claims 9 and 10 stand rejected under 35 U.S.C. § 112, first paragraph (enablement).

We affirm all obviousness rejections and vacate the enablement rejection. We also make a new ground of rejection of claims 9 and 10 under the provisions of 37 CFR § 1.196(b).

Discussion

There are two principal aspects of the claimed invention under review in this appeal. The first is oligonucleotides that comprise at least one 2-aminoadenosine nucleoside unit, at least one phosphorothioate internucleoside linkage, and at least one 5-substituted uridine or cytidine nucleoside unit. See claims 1-8. The second is a method of inhibiting expression of a gene by administering to cells or tissues the

claimed oligonucleotides or a method of treating a disease or condition associated with the expression of a gene by administering the claimed oligonucleotides.

As explained by appellants:

Oligonucleotides and their analogs have been developed for various uses in molecular biology, including use as probes, primers, linkers, adapters, and gene fragments. In a number of these applications, the oligonucleotides specifically hybridize to a target nucleic acid sequence. Hybridization is the sequence specific hydrogen bonding of oligonucleotides via Watson-Crick and/or Hoogsteen base pairs to RNA or DNA. The bases of such base pairs are said to be complementary to one another.

Specification, page 1, second paragraph. Appellants further explain:

It is greatly desired that oligonucleotides be able to be synthesized to have customized properties which are tailored for desired uses. Thus a number of chemical modifications have been introduced into oligonucleotides to increase their usefulness in diagnostics, as research reagents and as therapeutic entities. Such modifications include those designed to increase hybridization or binding to a target strand (i.e. increase their melting temperatures, T_m), to assist in identification of the oligonucleotide or an oligonucleotide-target complex, to increase cell penetration, to stabilize against nucleases and other enzymes that degrade or interfere with the structure or activity of the oligonucleotides, to provide a mode of disruption (a terminating event) once sequence-specifically bound to a target, to improve the pharmacokinetic properties of the oligonucleotide and to reduce immune stimulation.

Id., page 3, second paragraph.

As seen, the claimed oligonucleotides must have at least three chemical modifications, i.e., at least one 2-aminoadenosine nucleoside unit, at least one phosphorothioate internucleoside linkage, and at least one 5-substituted uridine or cytidine nucleoside unit. However, in the Background portion of the specification, appellants have indicated that each of the three claimed chemical modifications was

known in the prior art prior to the present invention and the use of combinations of the three chemical modifications was also known. For example, appellants state:

Phosphorothioate oligonucleotides, which incorporate a phosphorothioate internucleoside linkage (P=S), as opposed to a phosphodiester linkage (P=O), are very common modification and are presently being used as antisense agents in human clinical trials for various disease states, including use as antiviral, anticancer and anti-autoimmune agents.

Id., page 3, lines 19 through 23.

The incorporation of 2-aminoadenosine (2,6-diamino-purine) and similar moieties into oligonucleotides in place of adenosine provides an additional site for hydrogen bonding to uridine or thymidine. This modification has been shown to increase the binding affinity of oligonucleotides to their target RNA sequences and, to a lesser extent, DNA sequences (Gryaznov, S., et al., Tetrahedron Lett, **1994**, 35, 2489-2492).

Id., page 4, lines 3 through 7.

Modifications of the 5 position of cytosines has been found to be effective in reducing immune stimulation (Boggs, R.T., et al., Antisense Nucleic Acid Drug Dev., **1997**, 7, 462-471), particularly 5-methyl and 5-halo substitutions. In addition, these modifications may be increase [sic] hybridization of oligonucleotides to target. Substitution of a single cytosine with 5-methyl cytosine was also able to stabilize an oligonucleotide by increasing its T_M by 0.5°C (Sanghvi, Y.S. et al., Nucleic Acids Res., **1993**, 21, 3197-3203).

Id., page 4, lines 13 through 18.

Appellants also state that oligonucleotides containing both 2-aminoadenosine nucleoside and 5-methylcytidine as well as combinations of 5-methylcytosine and 2-aminoadenine have been used. See, e.g., specification, page 4, line 21 - page 5, line 5.

Discussion

1. Obviousness.

We affirm all of the obviousness rejections essentially for the reasons set forth by the examiner on pages 5 through 10 of the Examiner's Answer. Appellants do not dispute, and as seen from the Background portion of the specification they cannot dispute, that each of the three chemical modifications required in the oligonucleotides of claim 1 on appeal were known individually at the time of the present invention. Also, the Background portion of the specification and the prior art applied by the examiner reflects that the combinations of two of the three required chemical modifications were known at the time of the present invention. The only argument presented in the Appeal Brief in regard to the obviousness rejections is that the examiner has not adequately identified the requisite "motivation" to combine the references. For example, appellants state "[the references] do not so much as suggest combining 2-aminoadenine nucleosides, 5-substituted uridine or cytidine nucleotides and phosphorothioate interneucloside linkages within a single oligonucleotide." Appeal Brief, page 6. We disagree.

The examiner has thoroughly pointed out in each statement of rejection appearing in the Examiner's Answer the requisite "motivation" for combining the prior art teachings relied upon. For example, in regard to claims 1, 3 and 4, the examiner has determined that "Monia [986], Prosnyak, Gryaznov, and Buttinelli all teach the motivation of incorporation of modifications in either the internucleotide linkages, nucleobases or sugars of oligonucleotides in order to improve target binding and

stability. Furthermore, Monia ['986], Prosnyak, and Buttinelli all teach the motivation of combining such modifications into a single oligonucleotide for increasing target binding and increasing stability." Examiner's Answer, page 6. In similar fashion, the examiner has identified adequate "motivation" to combine the references in order to arrive at the subject matter of claims 2, and 5-8. Examiner's Answer, pages 7 - 10.

Since we find no error in the examiner's underlying fact finding or in the examiner's legal conclusion of obviousness, it follows that all of the obviousness rejections are affirmed.

2. Enablement.

The examiner has rejected claims 9 and 10 under the enablement requirement of 35 U.S.C. § 112. first paragraph, focusing on the purported lack of "in vivo efficacy of antisense." Examiner's Answer, page 10. In reviewing this issue, we note that Monia '986, one of the main references relied upon by the examiner in making obviousness rejections, is also directed to anitsense oligonucleotide inhibition, specifically of the ras gene. Claim 6 of Monia '986 reads as follows:

6. A method of modulating the expression of the human H-ras gene comprising contacting tissues or cells containing the gene with an antisense oligonucleotide comprising SEQ ID NO: 1 or SEQ ID NO: 2 having a phosphodiester or phosphorothioate internucleoside linkage.

The oligonucleotide having SEQ ID NO:2 in this application is stated to target "Human Ha-ras." Specification, page 33. Monia '986 is prior art to this application. Since it is an United States patent, claim 6 is presumed to be valid and thus enabled. 35 U.S.C. § 282.

In making the enablement rejection, the examiner has relied upon several references as evidence of the unpredictability in the antisense art. However, the examiner's analysis of the issue is incomplete as it does not appear to take into account relevant prior art such as Monia '986 or the fact that there has been some success with antisense oligonucleotides as therapeutic agents. See, e.g., specification, page 2, lines 28 - 30 ("Antisense oligonucleotides can also be therapeutic agents, with one antisense drug having been approved for use and several oligonucleotides currently undergoing clinical trials.")

Under these circumstances, we find it appropriate to vacate the examiner's enablement rejection and make the following new ground of rejection of claims 9 and 10 under the provisions of 35 U.S.C. § 103.

New Ground of Rejection Under 37 CFR § 1.196(b)

Claims 9 and 10 are rejected under 35 U.S.C. § 103(a). As evidence of obviousness, we rely upon Monia '986, Prosnyak, Buttinelli, and Gryaznov.

As explained above, the examiner has set forth adequate factual basis for concluding that the oligonucleotides required by claim 1 on appeal would have been obvious to one of ordinary skill in the art. In regard to claims 9 and 10, Monia '986 describes a method of inhibiting expression of a gene by administering an appropriate oligonucleotide. Since Monia '986 describes antisense oligonucleotide inhibition of the ras gene, we conclude that it would have been obvious to one of ordinary skill in the art to use the oligonucleotides found to have been obvious by the examiner to inhibit the ras gene as described by Monia '986.

In regard to claim 10 we note that the claim states that immune stimulation in the treated animal is reduced. However, appellants admit in the specification that modifications of the five position of cytosines has been found effective to reduce immune stimulation, particularly 5-methyl and 5-halo substitutions. Id., page 4. We note that claim 2 is directed to the oligonucleotide of claim 1 wherein said 5-substituent is bromo, fluoro, chloro, or iodo. And claim 3 is directed to the oligonucleotide of claim 1 wherein the 5 substituent is methyl. Since the examiner has correctly determined that the oligonucleotides of claims 2 and 3 would have been obvious to a person of ordinary skill in the art at the time of the present invention based upon the applied references, such oligonucleotides would possess the property of reducing immune stimulation in the patient.

Summary

We affirm the obviousness rejections of claims 1 through 8 and vacate the enablement rejection of claims 9 and 10. We institute a new ground of rejection under 37 CFR § 1.196(b) of claims 9 and 10.

Time Period for Response

In addition to affirming the examiner's rejection of one or more claims, this decision contains a new ground of rejection pursuant to 37 CFR § 1.196(b). 37 CFR § 1.196(b) provides, "[a] new ground of rejection shall not be considered final for purposes of judicial review."

Regarding any affirmed rejection, 37 CFR § 1.197(b) provides:

(b) Appellant may file a single request for rehearing within two months from the date of the original decision

37 CFR § 1.196(b) also provides that the appellant, WITHIN TWO MONTHS FROM THE DATE OF THE DECISION, must exercise one of the following two options with respect to the new ground of rejection to avoid termination of proceedings (37 CFR § 1.197(c)) as to the rejected claims:

(1) Submit an appropriate amendment of the claims so rejected or a showing of facts relating to the claims so rejected, or both, and have the matter reconsidered by the examiner, in which event the application will be remanded to the examiner. . . .


(2) Request that the application be reheard under § 1.197(b) by the Board of Patent Appeals and Interferences upon the same record. . . .

Should the appellant elect to prosecute further before the Primary Examiner pursuant to 37 CFR § 1.196(b)(1), in order to preserve the right to seek review under 35 U.S.C. §§ 141 or 145 with respect to the affirmed rejection, the effective date of the affirmance is deferred until conclusion of the prosecution before the examiner unless, as a mere incident to the limited prosecution, the affirmed rejection is overcome.

If the appellant elects prosecution before the examiner and this does not result in allowance of the application, abandonment or a second appeal, this case should be returned to the Board of Patent Appeals and Interferences for final action on the affirmed rejection, including any timely request for rehearing thereof.

No time period for taking any subsequent action in connection with this appeal
may be extended under 37 CFR § 1.136(a).


AFFIRMED-IN-PART; 37 CFR § 1.196



Sherman D. Winters
Administrative Patent Judge



William F. Smith
Administrative Patent Judge



Donald E. Adams
Administrative Patent Judge

)
)
)
)
)
) BOARD OF PATENT
)
) APPEALS AND
)
) INTERFERENCES
)
)

Appeal No. 2004-1394
Application No. 09/348,106

Page 12

Woodcock Washburn LLP
One Liberty Place
46th Floor
Philadelphia, PA 19103

dem